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Resumo 
 
Este relatório tem como objetivo descrever as atividades de estágio 
realizadas na Unidade de Gestão de Dados da Eurotrials, Consultores 
Científicos, como parte do 2º ano do Mestrado em Biomedicina 
Farmacêutica. Este estágio focou-se no desenvolvimento de competências e 
obtenção de experiência em atividades de Gestão de Dados Clínicos. 
 
No decurso do estágio tive oportunidade de complementar o conhecimento 
obtido na Licenciatura em Ciências Biomédicas e no Mestrado em 
Biomedicina Farmacêutica. Foram aprofundados e explorados os conceitos, 
requisitos e práticas inerentes à Gestão de Dados Clínicos e obteve-se uma 
visão única do ciclo de vida de um projeto de investigação clínica – a de 
uma CRO. 
 
Para além da aquisição de conhecimentos teóricos, este período de estágio 
foi fundamental para o desenvolvimento de um conjunto de aptidões sociais 
e pessoais que contribuíram para o meu crescimento profissional dentro da 
instituição de acolhimento. 
 
O presente documento começa por expôr os príncipios teóricos que servem 
de base à atividade do Gestor de Dados Clínicos. Seguidamente, são 
detalhados os componentes genéricos e específicos de treino adquiridos 
durante o período de estágio. Depois da apresentação das atividades de 
estágio, são discutidos os vários desafios enfrentados e é feito um balanço 
pessoal desta experiência. 
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Abstract 
 
The aim of this report is to describe the training activities carried out at the 
Data Management Sub-Unit of Eurotrials, Scientific Consultants, as part of 
the 2nd  year of the Master’s Program in Pharmaceutical Medicine. This 
internship was focused on the development of skills and on gaining 
experience in Clinical Data Management activities. 
 
Over the course of this internship, I had the opportunity to build upon the 
knowledge obtained in the Bachelor’s Degree in Biomedical Sciences and in 
the Master’s Program in Pharmaceutical Medicine. Concepts, requirements 
and practices related to Clinical Data Management were explored and 
strengthened throghout. Furthermore, an unique perspective on the lifecycle 
of clinical research projects was obtained – that of a CRO. 
 
Besides the acquisition of theoretical knowledge, this training period was 
paramount for the development of a number of social and personal skills that 
contributed for my profissional growth within the host institution. 
 
This document begins by a description of the theoretical principles that set 
the ground for the Clinical Data Manager’s work. Then, the generic and 
specific training elements of the curricular training are detailed. After 
presenting my training activities, I discuss the various challenges I had to 
overcome during these 9 months. Finally, some personal remarks and 
conclusions are presented. 
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1. Introduction  
This report is an account of the 9-month internship I undertook at the Data Management Sub-Unit 
of Eurotrials, Scientific Consultants, as a part of the second year curricular activities of the 
Master’s Degree in Pharmaceutical Medicine. 
 
As a Data Management Trainee, I was actively involved in the various Data Management activities 
carried out during the course of both interventional and observational clinical studies.  This 
document describes not only the tasks I performed, but also my objectives for, expectations and 
overall thoughts on this training experience.  
 
This internship was conducted under the supervision of Ana Patacão, Clinical Data Global Director 
at Eurotrials, Scientific Consultants, and Professor Bruno Gago, Invited Auxillary Professor at the 
University of Aveiro. 
 
1.1 Objectives 
The objectives established for this curricular internship were the following: 
 Primary objective: 
› To gain knowledge and experience in the tasks associated with projects and 
services falling under the scope of Clinical Data Management. 
 Secondary objectives: 
› To consolidate and build upon the knowledge acquired during the Bachelor’s 
Degree in Biomedical Sciences and the Master’s Program in Pharmaceutical 
Medicine through practical experience. 
› To understand the inner workings of a Clinical Research Organization (CRO) and 
their role in clinical research. 
› To improve the interpersonal skills needed to successfully operate in a 
professional, team-based environment, such as communication skills, 
accountability, autonomy, proactivity and assertiveness.  
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1.2 Structure of the Report 
This report consists of five chapters, including this introduction containing the objectives of my 
curricular internship and a brief presentation of the host organization, with an emphasis on the 
Data Management Sub-Unit.  The remaining chapters contain: 
 Chapter 2 - State-of-the-art: the State-of-the-art in clinical research, with a focus on 
Clinical Data Management and the CRO business.  
 Chapter 3 - General Training: a presentation and discussion on the theoretical training I 
underwent at Eurotrials, Scientific Consultants and which provided the ground for 
developing the various practical activities. 
 Chapter 4 - On-the-job Training: a description and discussion of the Clinical Data 
Management activities performed throughout the internship.  
 Chapter 5 - Discussion:  a discussion on the major learning points of the internship, as well 
as on the difficulties faced during its course and the strategies adopted to overcome 
them. 
 Chapter 6 - Conclusion: final remarks on the curricular internship and on the achievement 
of its objectives. 
 
1.3 The Host Institution: Eurotrials, Scientific Consultants 
Eurotrials, Scientific Consultants, is a Portuguese, privately owned CRO founded in 1995 in Lisbon 
by members of academia, the medical community and the pharmaceutical industry (1). It 
operates in Europe and Latin America, more specifically Portugal, Spain, Brazil, Argentina, Chile 
and Mexico, both with its own local operation centers and in partnership with other companies 
from its base headquarters in Portugal. 
 
As a full-service CRO, Eurotrials offers a vast range of services in the areas of health and clinical 
research, including consulting and training services (1). It possesses the necessary experience and 
expertise, distributed across its various departments, to participate in all stages of drug, biological 
product and medical device development.  
 
Throughout the years, Eurotrials Portugal has received a number of certifications, namely (2): 
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 The ISO 9001 quality certification from Lloyd’s Register Quality Assurance with UKAS (UK 
Accreditation Service) in early 2001, and its subsequent transitions to ISO 9001:2000 in 
December 2002 and ISO 9001:2008 in March 2009. 
 The Rede PME Inovação COTEC recognition in May 2007. 
 The Leading SME recognition in September 2007. 
 Representation on the board of Health Cluster Portugal, in the person of Maria João 
Queiroz, MD, Eurotrials’ Global CEO. 
  SIFIDE II recognition, for its suitability in the areas of process development and R&D 
project.  
Eurotrials Portugal’s internal organization is depicted on Figure 1. 
 
  
Figure 1 – Eurotrials Portugal’s organizational chart 
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1.3.1 Overview of the Data Management Sub-Unit 
 
Eurotrials’ Data Management Sub-Unit (SU) is a part of the Clinical Data Business Unit and it 
was where I developed my internship activities. This department is responsible for all clinical 
data management services provided by the company, not only in Portugal but across all of 
Eurotrials’ operating regions (3). The Data Management SU is highly qualified and 
experienced and offers several services and solutions, including (3): 
 Data Management services for Phase I-IV clinical studies, covering a wide range of 
therapeutic areas. 
 Case Report Form (CRF) development (both paper CRFs and electronic CRFs (eCRF)). 
 Database development. 
 Standards implementation (namely CDISC-CDASH and SDTM). 
 Electronic Data Capture (eDC) solutions, including FDA 21 CRF Part 11 compliant 
systems and non-FDA 21 CRF Part 11 compliant Web Portals. 
 
Figure 2 illustrates the proportion of clinical trials and observational studies on which 
Eurotrials’ Data Management Unit is currently working. Figure 3 shows the number of each 
type of CDM solution (eDC and paper CRF) used by Eurotrials’ CDM team since 2013. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 – Proportion of clinical trials and observational studies currently under the responsibility of Eurotrials’ Data 
Management SU. 
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Figure 3 – Proportion of eDC and paper CRF solutions employed in Eurotrial’s Data Management Unit since 2013  
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2. State-of-the-art 
This section provides an overview of the current state of the art in clinical research, focusing on: 
Contract Research Organizations, since it was in this context that my internship took place; clinical 
research studies, in order to clarify the background within which Clinical Data Management (CDM) 
operates; the current CDM landscape, relating directly to the field of work where I developed my 
curricular internship activities. 
 
2.1 Clinical Research Organizations 
According to the International Conference on Harmonization (ICH) Guideline on Good Clinical 
Practice (GCP) E6 (R1), a CRO is “a person or an organization (commercial, academic, or other) 
contracted by the sponsor to perform one or more of a sponsor's trial-related duties and 
functions”. Under the framework of this guideline, a sponsor is “an individual, company, 
institution, or organization which takes responsibility for the initiation, management, and/or 
financing of a clinical trial”(4). 
 
CROs provide clinical trial and other research support services for the pharmaceutical, 
biotechnology and medical device industries, as well as for universities, foundations and other 
research institutions (5). Organizations contract with CROs, i.e., outsource a certain service or 
group of services to a CRO, in order to access specialist capability and knowledge without hiring 
permanent staff or building that expertise in-house.  
 
The origins of the outsourcing of drug development activities to external partners can be traced 
back to the 1940s and 1950s (6). At this time, companies like Huntingdon Life Sciences and 
Charles River Laboratories provided animals for clients to experiment on or conducted the tests 
themselves. But it was only in the 1980s and the 1990s, when the pharmaceutical industry began 
flourishing with the arrival of a stream of blockbuster drugs, that the CRO business started to 
grow.  
 
Blockbuster drugs provided CROs with the perfect opportunity to expand, because despite the 
overwhelming profits that they generated, they also originated a staggering rise in costs for the 
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pharmaceutical industry. Expenses had to be cut and CROs offered an added-value service that 
allowed the pharmaceutical companies to do just that.  
 
The immediate availability of expert personnel, knowledge and equipment at virtually any 
geography precludes the making of any great investments by the sponsor while ensuring that any 
and all drug discovery and development activities are carried out by the highest standards.  CRO 
services went from comprising about only 4% of R&D expenses for a pharmaceutical company in 
the early 90s to an impressive 50% in the mid 2000s (6).  
 
As the market matured, so did the part played by CROs in drug development. Mergers and 
acquisitions were made and some companies evolved from providing mere niche services to 
broadening out their offer to include clinical trial management, statistics, data management and 
more. Today, if a pharmaceutical company wishes to, it can outsource the entire process of drug 
discovery and development to CROs (6). Naturally, each company’s outsourcing philosophy is 
different, depending on its goals and culture. Some clients do outsource all study-related 
activities, whereas others prefer to outsource only very specific services (7). It is important to 
note that, as per ICH’s GCP, even if a company transfers all of study-related functions to a CRO, 
the final responsibility of trial data integrity and quality remains with it, as the sponsor (4) of the 
study. 
 
The relationship between the clinical study sponsor and the CRO has also evolved over the course 
of time. For the first two decades of the CRO industry, CROs were treated like, and acted as, 
“order takers”. With the experience and maturity brought upon by time, CROs went from mere 
vendors to dependable partners. Today, biopharmaceutical companies are counting on, trusting 
and partnering with service providers to bring their products to the marketplace (8).  
 
This evolution has had natural reflections in market size and growth. In December 2007, Goldman 
Sachs estimated that the Phase II-III outsourcing market would increase roughly 16% from 2006 to 
2011 and estimated the total CRO market to be worth over US $29B annually in 2011 (8). 
According to a report from business information provider Visiongain, revenues for CROs are 
expected to reach US $32.73 billion in 2015 (9). Furthermore, worldwide, the CRO outsourcing 
activities accounted for 25.3% of the total pharmaceutical expenditure on R&D in 2010 – a value 
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estimated to reach 37.1% in 2018 (5). Under the light of these numbers, it can be argued that, for 
an industry that is fairly recent, CROs as a whole have been performing outstandingly well (5). 
 
2.2 Overview of Clinical Research Studies 
The growth and development witnessed in the field of clinical research over the past 50 years is 
quite possibly unparalleled (10). A huge leap in knowledge has been taken from the very first 
randomized controlled trial (RCT), published in 1948, to the present era of evidence-based 
medicine strongly supported by what is known as real world data (RWD) . The design of clinical 
studies and the tools used to collect and assess data have been refined. Nowadays, an assortment 
of methodologies exists to meet the needs of a vast range of clinical specialties and stakeholders, 
including regulatory bodies, payers and patients (10).  
 
Since I had the chance to develop my training activities within the context of both clinical trials 
and observational studies, the two following sections present a brief characterization of both 
types of clinical studies in current times. 
 
2.2.1 Clinical Trials 
 
The ICH Guideline on GCP E6 (R1), defines clinical trial as “any investigation in human subjects 
intended to discover or verify the clinical, pharmacological and/or other pharmacodynamic 
effects of an investigational product(s), and/or to identify any adverse reactions to an 
investigational product(s), and/or to study absorption, distribution, metabolism, and excretion of 
an investigational product(s) with the object of ascertaining its safety and/or efficacy” (4). While 
this concept, as we see it today, is relatively recent, the roots of the modern controlled clinical 
trial can be traced back to the 18th century. In 1753, James Lind conducted a pioneer trial of six 
potential remedies for scurvy aboard a British Navy ship. This trial was open, had no placebo 
control and used a very small patient population, but lead to profound changes in clinical practice, 
improved the health of countless people, and set the ground for future researchers (11). 
 
Nowadays, the clinical trial, more specifically the RCT, is an essential part of drug development. Its 
distinct features make it the most reliable tool for establishing a causal relationship between 
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intervention and outcome (12): randomization guarantees that the assignment to treatment 
groups is arbitrary, balanced and uninfluenced by preferences or characteristics of the patient and 
the physician; blinding minimizes the risk of bias in comparing treatments (13); prospective 
assignment, guarantees that the intervention precedes the outcome, thus allowing for causation 
to be ascertained. 
 
Placebo-controlled trials are the usually preferred type of RCTs, since they enable the 
determination of the absolute efficacy of an intervention. However, this is not always the most 
ethical methodology to employ and, as such, consideration should be given to the characteristics 
of the intervention at hand, as well as to the characteristics of its patient population (12).  
 
Clinical trials are conventionally classified according to the four temporal phases (Phases I-IV) in 
which clinical drug development is divided. However, this is recognized by ICH as not the most 
accurate basis for the classification of clinical trials, given that the same type of trial can occur in 
different phases of drug development. A classification system based on study objectives is instead 
proposed. This system divides clinical trials in the following categories (14):  
 Human Pharmacology clinical trials: typically performed during the first Phase of 
development, when a new drug is first administered to humans, these studies aim to 
assess a drug’s pharmacokinetics (PK) and pharmacodynamics (PD), assess its tolerability, 
determine its metabolism and drug interactions and make initial estimates of activity (14).  
 Therapeutic Exploratory clinical trials: typically Phase II studies, these studies aim at 
exploring the therapeutic efficacy of the drug in a select group of members of the target 
population. The most adequate dosages to use in later studies (14) are determined in 
these studies. 
 Therapeutic Confirmatory clinical trials: typically Phase III studies, these trials are aimed at 
demonstrating/confirming the therapeutic efficacy of the medicinal product. They usually 
involve larger patient populations, enabling the collection of data to confirm the safety 
and efficacy information collected in previous studies. They are intended to provide an 
adequate basis for marketing approval (14). 
 Therapeutic Use clinical trials: generally conducted after drug approval (Phase IV of 
development), these studies may be of any of the types described above. These include 
studies that were not deemed necessary to obtain marketing approval, but which are 
considered important to optimize drug use (14).  
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The realization that dividing clinical trials by phases is not quite accurate is closely linked to the 
novel, but growing, notion that the typical Phase I through IV development sequence might not 
be the most adequate (14) for most medicinal products. In fact, as the pharmaceutical industry’s 
conventional R&D model proves less and less effective over time, it seems only natural that such a 
sequential strategy should be replaced sooner than later.  
 
Despite large R&D investments and great technological advancements, the number of new drug 
applications approved by the major regulatory bodies around the world has decreased 
significantly (15). This low approval rate is compounded by the rising costs in drug development. 
According to several estimates, it may cost as much as US $1 billion dollars to take a drug from 
concept to market. The notably high attrition rates in late Phase II and Phase III have also 
contributed to the rising burden on R&D budgets (16). Moreover, key patent expirations between 
2010 and 2014 have been estimated to put more than US $209 billion in annual drug sales at risk, 
with US $113 billion of sales being lost to generic substitution (15). 
 
To address the issue of impaired R&D productivity, a new paradigm for drug development has 
been proposed: the “quick win, fast fail” paradigm (Figure 4). In this new model, technical 
uncertainty about a new drug is removed before the expensive later development stages through 
the establishment of proof-of-concept (POC).  These POC studies conducted in men early in 
development, combined with other scientific and technological innovations (e.g. more 
appropriate animal models, biomarkers,  etc.) (17) allow attrition to also occur at an earlier stage. 
  
 
 
 
 
 
 
 
 
 
 
Figure 4 – The new “quick win, fast fail” paradigm of drug development. Adapted from (15) 
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This will mean that fewer drugs will be advancing into Phase II and III, but those that do will have 
higher probabilities of success and of being approved later on. R&D investments in late-stage will 
be reduced, thus making more funds available to further enhance R&D productivity (15). 
 
2.2.2 Observational Studies 
 
In observational studies, the investigators do not control or manipulate the “exposure” or 
intervention on subjects. They draw conclusions on the effects of that intervention by directly 
observing individuals in their natural setting. In these studies, the decision to apply the 
therapeutic strategy under assessment to any patient should be determined by clinical 
preferences, policy decisions or practice patterns, as opposed to a study protocol (18).  
 
Observational studies allow investigators to establish correlations between variables, such as 
between patient characteristics or therapies and a given outcome (12). Observational study 
designs include: 
 The cross-sectional study, where risk factors and outcome data are collected in a group at 
one specific point in time and data are examined for correlations (12). 
 The case-controlled study, where a group of individuals with a disease is compared with a 
group without that same disease and past risk factors are explored in both groups to try 
and determine which of those contributed to disease development (12). 
 The cohort study, where two groups, one with a risk factor and one without that risk 
factor, are followed prospectively to assess the eventual development of a disease (12). 
 
Data for observational research can have one of two origins. Data that is collected by the 
investigators for the specific purpose of answering the study’s objectives is known as primary 
data. Data that has already been collected for another reason but is used by the investigator to 
answer a new research question is known as secondary data (18). 
 
For centuries, observational studies formed the basis of clinical research, from Leonardo da Vinci’s 
studies on human anatomy to William Harvey’s discovery of the circulation of the blood (19). But 
even though RCTs are currently the gold standard for evaluating the safety and efficacy of 
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healthcare interventions (20), the medical community still relies heavily on observation studies to 
describe health, disease and associated patterns (19). 
 
While it is a fact that observational studies have some limitations relative to experimental studies 
(for instances, the lack of blinding and randomization increases confounding), well-designed 
observational studies are essential to the overall scientific understanding of a particular exposure-
outcome association. The controlled environments of a clinical trial do not include the many 
practical issues encountered in clinical practice (12, 21). Observational studies, on the other hand, 
typically allow for the study of efficacy, safety, tolerability and compliance in large, diverse patient 
populations. Less common, yet serious, adverse events can be identified and, overall, clinically 
significant differences on treatment effects can be detected (20). Consequently, observational 
studies may be an important addition to the clinician’s resources by complementing RCT data 
with real-world information. 
 
In fact, the concept of RWD has gathered much attention in recent years as a tool for assessing 
the value of a new medicinal product or technology. RWD was defined by the International 
Society for Pharmacoeconomics and Outcomes Research’s (ISPOR) Real-Word Data Task Force as 
“data used for clinical, coverage, and payment decision-making that are not collected in 
conventional RCTs” (22). Observational studies are a good source of RWD, but they are not the 
only one. Other possible sources of RWD include: patient and population surveys, patient chart 
reviews, and registries (23).  
 
As discussed above, the natural constraints imposed by clinical trials limit the collection of 
relevant data on health technologies and RWD is valuable in that it helps overcoming that lack of 
information. This move to collect RWD is fairly new and is happening quite rapidly (23). This has 
happened especially because decision-makers have recognized the need for more robust 
evidence around the true effectiveness and safety of medicines before deciding on coverage and 
reimbursement measures (24). 
 
However, the potential of RWD extends beyond that. It can be used, for instance, to inform drug 
development strategies, to better design treatment algorithms and to support innovative ways of 
optimized healthcare delivery  (22). In short, RWD fills in the blanks left by RCTs. By doing that, it 
delivers information necessary for everyone across the healthcare setting: payers can better 
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understand the cost-effectiveness and value for money of the product; healthcare professionals 
learn how to better manage patients; and pharmaceutical companies can capitalize on the full 
value of their products (25). 
 
2.3 Clinical Data Management Landscape 
CDM can be defined as the set of activities carried out to develop, execute and supervise the 
plans, programs and practices that allow the collection, control, protection and value 
enhancement of clinical trial data (26). The objective of the CDM team is not only to ensure that 
the necessary information is captured in each clinical study, but also to guarantee the validity, 
quality and integrity of the collected data. The ultimate goal of the CDM team is to deliver a clean, 
high-quality database for statistical analysis, so that any conclusions drawn on the medicinal 
product under investigation are robust and reliable (13). 
 
The focus put on clinical trial data, especially as a recognized key corporate asset in today’s 
biopharmaceutical industry, has made CDM an activity of increasing importance. By way of its 
cross-functional, complex and dynamic nature, CDM has globally grown as a firmly established 
discipline. It is vital for obtaining a reliable and effective base that can support not only marketing 
authorization applications, but also corporate strategic planning, decision-making, process 
improvement and operational optimization (26).  
 
2.3.1 Regulatory Requirements and Standards in Clinical Data Management 
 
The requirements for the development and maintenance of an appropriate CDM environment are 
found in regulations and guidelines set forth by regulatory agencies, by the ICH and by other 
organizations within the field, such as the Society for Clinical Data Management (SCDM). Many of 
these regulations and standards set the expectation for certain Standard Operating Procedures 
(SOPs) governing particular processes at the sponsor, CRO and/or clinical study site level. 
Although complex, the observation of these requirements is key for ensuring the validity and 
reliability of the collected data in any clinical study. The most relevant requirements and 
standards for the CDM process are detailed below. 
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ICH Guideline on Good Clinical Practice E6 (R1) 
The ICH guideline on GCP sets forth the standards for the design, conduct and report of clinical 
trials. Compliance with these standards guarantees that the subjects’ rights, safety and well-being 
are protected throughout the course of a trial and that clinical trial data are of high-quality and 
integrity (4, 27). GCP requirements on data management are mostly unspecific at the technical 
level and data management is seldom mentioned throughout the document, but many of the 
general principles and definitions present in this guideline do apply to CDM activities (28). Table 1 
summarizes the contents of the ICH guideline on GCP that relate to CDM. 
 
Table 1 - ICH’s GCP guideline requirements applicable to CDM 
Section Subject(s) 
Glossary Various relevant definitions (e.g. audit trail, source data, source 
documents, CRF, etc.) 
The Principles of the ICH GCP Record confidentiality 
Clinical trial information recording, handling and storage 
Records and Reports Investigator responsibilities with regards to CRF completion, 
consistency of CRF data with source documents and 
maintenance of an audit trail for clinical trial data 
Quality Assurance and Quality Control Implementation of quality assurance and quality control systems 
Trial Management, Data Handling and 
Record Keeping 
Personnel qualification 
Electronic trial data handling and/or remote electronic trial data 
systems 
Subject identification codes for identification of data reported to 
each subject 
Traceability of data transformations during processing 
Monitoring Responsibilities of the clinical trial monitor in ensuring proper 
data collection and clinical trial documentation. 
Essential Documents for the Conduct 
of a Clinical Trial 
Mentions to the CRF (sample CRF, revisions of CRFs, signed, 
dated and completed CRFs, documentation of CFR corrections), 
source documents and signature sheets. 
 
Food and Drug Administration’s Title 21 CFR Part 11 
The Food and Drug Administration’s (FDA) Title 21 CFR Part 11 describes the criteria under which 
this agency considers electronic records to be equivalent to paper records and electronic 
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signatures, as well as handwritten signatures executed to electronic records to be equivalent to 
handwritten signatures executed on paper (29). It is applicable to any records required by or 
submitted to the FDA under agency regulations (13). Electronic Clinical Data Management 
Systems (CDMS) used in clinical trials intended to support New Drug Applications (NDA) are 
expected to be fully compliant with 21 CFR Part 11. 
 
This regulation was designed with the main goals of ensuring data authenticity, system and data 
integrity, data confidentiality and the non-repudiation of electronic signatures. The areas covered 
by this ruling are those seen by the FDA as the ones with a higher likelihood of failure that could 
lead to data misappropriation (30). They are: 
 System validation: systems should be validated, i.e., shown to be consistent, reliable and 
fit to use (30). 
 Records management: appropriate procedures should be in place for record creation, 
modification, maintenance and transmission, to guarantee their authenticity and 
integrity. Furthermore, systems must retain electronic records accurately and reliably 
(13). Specific requirements and controls for all phases of an electronic record life cycle are 
outlined by the regulation. 
 System security management: system owners should limit access to the system and know 
who is accessing and altering the system data at all times. Minimum standards and 
specific controls for security (30) are described. 
 Audit trail management: systems should incorporate audit trail capabilities to keep track 
of record creation, modification and elimination. 
 System documentation management: systems must be able to generate controlled 
documentation throughout its own life cycle, so as to provide evidence that the system 
complies with FDA’s 21 CFR Part 11 (13). 
 Electronic signature management 
 Certification: individuals granted access to the systems must be trained and certified prior 
to accessing and using them (30). 
 
Good Clinical Data Management Practices 
The Good Clinical Data Management Practices (GCDMP) is a reference document prepared by the 
SCDM, reflecting the views of its members on what constitutes best practice in CDM. Their main 
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purpose is to provide guidance on accepted practices for the many areas of CDM that are not 
covered by regulations and guidance documents currently in force. Furthermore, they intend to 
provide suggestions on how to meet the guidelines they recommend (31). 
 
It addresses CDM activities in 20 chapters. For each there are two types of recommendations: 
Minimum Standards, which ensure data integrity; and Best Practices, which in addition to data 
integrity offer higher efficiency, quality and lower risks. Each chapter contains recommended 
SOPs as well (31). This guidance is not endorsed by regulatory agencies, the industry, CROs or the 
academic community. It is not an exhaustive document and none of its recommendations 
supersede regulations or regulatory guidelines (31). Nevertheless, it is a highly regarded and 
widely employed document. 
 
CDISC Standards 
The Clinical Data Interchange Standard Consortium (CDISC) is a non-profit organization that has 
released a number of standards and models for the acquisition, exchange, submission and archive 
of clinical research data and metadata (32). These standards are vendor-neutral, platform-
independent and freely available to all in the organization’s website. Figure 5 depicts some of the 
CDISC standards for data, including those at the data content level, additional standards that help 
in exchange/share data, further clarify data, and make implementation choices that are 
appropriate for specific therapeutic areas (33). 
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Figure 5 – CDSIC standards for clinical research data. CDASH: Clinical Data Acquisition Standards Harmonization; SDTM: 
Study Data Tabulation Model; SEND: Standard for Exchange of Non-Clinical Data; SDM: Study Design Model; ODM: 
Operational Data Model; BRIDG: Biomedical Research Integrated Domain Group. 
 
Each of the standards fulfills a specific purpose within CDM and can be divided in three 
categories. 
 
Data Content Standards 
 Protocol Representation Model (PRM): developed to support the production of the study 
protocol document (34). 
 Clinical Data Acquisition Standards Harmonization (CDASH):  a set of recommendations 
for data collection fields across 18 domains, including adverse events, demographic data 
and other information that is common to most phases of clinical research and to most 
therapeutic areas (35). 
 Laboratory Data Model (LAB): a set of standards for data transfers between laboratories 
and clients (e.g. such as from a central lab to a study sponsor) (33). 
 Study Data Tabulation Model (SDTM): defines standards for the submission of data from 
clinical trials in tabular form (36). 
 Standard for Exchange of Non-Clinical Data (SEND): an equivalent of STDM applicable to 
non-clinical studies (33).  
 Analysis Data Model (ADaM): provides a format for the representation of clinical data, 
considering the specific needs of data analysis (33). 
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Data Exchange Standards 
 Study/Trial Design Model (SDM-XML): a standard for the interchange of rigorous, 
machine-readable descriptions of clinical studies’ designs (37). 
 Operational Data Model (ODM-XML): a model for the interchange and archive of clinical 
study data, with its associated metadata, administrative data, reference data and audit 
information (38). 
 Define-XML: a standard for transmission of metadata for SDTM, SEND and ADaM datasets 
(39). 
 Dataset-XML: its goal is to support the interchange of tabular data for clinical research 
applications using ODM-based XML technologies. It is based on the ODM standard and 
should follow the metadata structure defined in the Define-XML standard. 
 
Semantics Standards 
 Glossary: includes terminology and acronyms typically used in the industry (33). 
 Controlled Terminology: a set of standard expressions (or values) used across all CDISC 
standards (40).  
 Biomedical Research Integrated Domain Group (BRIDG): a conceptual representation of 
protocol-driven clinical/biomedical research, developed with the goal of providing a 
semantic basis for standards harmonization within the clinical research domain and 
between biomedical/clinical research and healthcare (41, 42). 
 
In addition to the above general standards, CDISC is actively collaborating with a number of 
partners on the development of specific Therapeutic Area Data Standards across various critical 
areas (e.g. Diabetes, Parkinson’s disease, etc.) (43). With its CDISC Healthcare Link Initiative, it is 
also working to strengthen the link between electronic healthcare records (EHRs) at healthcare 
sites and clinical research (44).   
 
Other guidance 
Notwithstanding the existence of various requirements and standards applicable to the activities 
of CDM, there is still a perceived lack of clarity on how to translate those principles into practice. 
This has lead to a considerable heterogeneity between different software products used in CDM. 
Furthermore, many of these requirements are of such complexity that they can only be met by 
organizations with ample resources. The limited human and financial resources of most academic 
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trial units hamper their CDM capabilities. This is a very significant barrier to the contribution of 
these academic units to clinical research, which is nowadays recognized to be of great value (45).   
 
Upon the realization of this issue, the European Clinical Research Infrastructures Network (ECRIN), 
an European forum established for the support of clinical research in Europe, developed a set of 
standard requirements for CDM and the associated IT infrastructure.  These standards, first made 
public in 2011 and updated in 2013, are GCP-compliant, and specific for European academic 
clinical research centers (45).  
 
The ECRIN requirements are divided into an IT and a DM part and were kept specific enough to be 
useful but generic enough to cover national standards where they existed. They are freely 
available and, with the appropriate adjustments following pilot implementations and audits, have 
proved to be able to bring academic data centers to a high level of quality with great flexibility 
(45, 46).  
 
Quality standards for source data and source documentation of electronic origin have also been 
the subject of much discussion by regulatory entities in recent years. Computerized systems have 
been increasingly used in clinical trials to generate and maintain source data and source 
documentation. In order to guarantee that data integrity is maintained, it is important to ensure 
that those systems meet the requirements for data quality that are expected for paper records 
(47). In May 2007, the US FDA published the “Guidance for Industry: Computerized Systems Used 
in Clinical Investigations”, providing orientation on the best practices in handling electronic source 
data and source documentation so as to provide a high degree of confidence in their reliability, 
integrity and quality. 
 
In 2010, the EMA published a similar document titled “Reflection paper on expectations for 
electronic source data and data transcribed to electronic data collection tools in clinical trials”, 
providing a contextual framework for the use of electronic source documents and data 
transcribed from paper source documents to eCRFs (48). 
 
These two documents cover related topics and both transmit intent to promote the use of 
electronic source data and source documentation, as well as the expectations of the regulatory 
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authorities for electronic source data and source documentation (48) – especially in respect to 
GCP compliance.  
 
Standard Operating Procedures 
SOPs are “detailed, written instructions to achieve uniformity of the performance of a specific 
function” (4). Under the ICH guideline on GCP, clinical trial sponsors are required to implement 
standard procedures covering all key activities of the conduct of the study as part of an 
appropriate quality assurance/quality control system. Ideally, these procedures should be 
overarching and not trial specific (27). An SOP should answer the questions: “Who?” “What?” 
“Where?” “When?” and “How?” in relation to the task that it is addressing (49). 
 
SOPs specific to data management need to cover all the elements of the data management 
process. The number and granularity of the SOPs depends on the institution’s own organization, 
activities and goals. SOPs should be in accordance with the latest regulatory requirements and 
guidelines. They should be sufficiently detailed to ensure that the tasks are consistently carried 
out, but not so much as to allow recurrent violations of the procedure due to normal variations in 
working. Compliance with SOPs is demonstrated through the appropriate forms, documents or 
checklists, which should be laid down beforehand in the SOP itself (49). 
 
Before an SOP or a new version of an existing SOP is implemented, staff that will be using it must 
be trained in its contents. Documentation of the training should go in the employees’ training log 
(27). This is one way of ensuring that the SOP is being complied with and that the staff knows the 
procedures by which they should perform their duties. 
 
The way a task is performed changes over time, and so do systems and regulations. Similarly, 
SOPs are not static documents and should be reviewed and updated regularly. As a general rule, 
SOPs are expected to be reviewed every one to two years (27) and many companies have written 
the requirements for SOP review in company-wide policies and procedures (49). While staff is 
usually reluctant to frequent SOP reviews and changes in practice, it is important to reinforce the 
pertinence of reviews as a way of improving processes, revisit the existing working tools and 
overall guarantee that the SOP better serves the clinical data manager. 
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2.3.2 Clinical Data Management Systems 
 
CDMSs are complex and specialized computer applications used by CDM teams to carry out their 
data management activities. These systems possess two major components: an underlying 
database, where clinical study data are stored; and a user interface, that takes the user’s 
instructions and applies them to the objects in the database (49). 
 
At a bare minimum, an acceptable CDMS should allow the CDM team to perform the following 
essential tasks (49): 
 Database design 
 Entry screen creation 
 Data entry 
 Data cleaning  
 Discrepancy management  
 Database lock 
 Data extraction 
 Management of user accounts and accesses to the system 
 
Many systems also support other features, such as automatic coding against various medical 
dictionaries. Compliance with FDA’s 21 CFR Part 11 is a mandatory feature if the system is to be 
used to carry out CDM activities for studies intended to support NDAs (49). 
 
CDMSs are more than mere data entry tools and, nowadays, there is a myriad of CDMSs available 
from multiple vendors. Some support more data management tasks and require more resources 
to be implemented and used than others. The way each task is performed varies significantly 
between systems, and they all have their bugs and problems (49). Ultimately, it is up to each 
company, institution or research group to select the system they see fit in light of their own 
needs, objectives and preferences. 
 
But one of the major problems of most of the currently existing CDMSs is that they are very 
elaborate and expensive. While this is not an issue for most pharmaceutical companies and CROs, 
which have plenty of human and financial resources, they are difficult to be acquired by academic 
clinical research centers, individual investigators or groups based in developing countries. The 
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alternatives to these non-commercial trial sponsors are: not complying with international data 
standards; or sending data to be processed off-site, which can also be very costly (50).  
 
The development of web-based, open-source CDMSs has been proving to be the best solution for 
this issue (50). Some open-source solutions are already accessible for use. The TrialDB system was 
the pioneer of open-source CDMS, initiated in the 1990s. OpenClinica and Clinovo’s ClinCapture 
are the two most popular open-source systems today (51). The ubiquity of open source systems is 
increasing, not only because they are free to download and use, but because they have a low or 
even free cost of maintenance and are fairly easy to use. Moreover, they can be customized to 
the requirements of the end users (though that usually requires significant programming skills) 
(52).  
 
The decrease in expenses allowed by open-source CDMSs empowers academic investigators 
worldwide to conduct trials, including in resource-poor settings where high-standard research is 
limited but often important for scientific advancement. In the long run, this approach could also 
be interesting for commercial trial sponsors, given the likely savings that it would originate (50) 
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3. Training Experience 
3.1  General Training 
Besides the on-the-job training activities, which relate to my practical training in Data 
Management and will be described in the next section, I had the chance to do a few general 
trainings during my curricular internship. These trainings were essential, as they provided me with 
complementary knowledge to understand the scope of the Data Management activities I 
participated in, as well as the organizational context in which I was included. These general 
trainings can be divided in two broad categories: job-specific trainings and project-specific 
trainings.  
 
Job-specific trainings were all that related to my role as a member of the Data Management Sub-
Unit. This included the reading of the company’s Quality Manual, Code of Business Conduct and 
Ethics and applicable SOPs. Additionally, I was required to read specific regulatory guidelines, such 
as ICH’s Guideline on GCP (E6). Two other job-specific trainings that were key during this 
internship were: 
 The company’s annual pharmacovigilance training. This training was important to 
understand the role and responsibilities that Eurotrials’ employees hold in this field, not 
only to its clients but also in a more general sense. 
 The formal training on medical coding using the Medical Dictionary for Regulatory 
Activities (MedDRA). Even though I had already worked with this dictionary in the past, 
this training was paramount to prepare me for the various coding tasks I was assigned 
afterwards, especially for the writing of an SOP on the subject. 
Project-specific trainings were all that related to my involvement in particular projects or studies. 
In most cases, this entailed reading the clinical study protocol, the Data Management Plan (DMP) 
and any other related documents whenever necessary. The reading of this documentation before 
collaborating in a new project was essential to fully comprehend its focus, direction and 
objectives. 
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3.2 On-the-job Training 
During my internship at Eurotrial’s Data Management Sub-Unit, I had the opportunity to be 
involved in various CDM activities, spanning the range of tasks typically assigned to the clinical 
data manager during the course of a clinical study (Figure 6). Some of the activities were 
performed more than once, allowing me to better grasp the concepts and understand the 
practices. Having the opportunity I had to be involved in the activities of so many different studies 
also allowed me to learn about the differences in CDM depending on the type of clinical study 
(observational studies vs. clinical trials) and on the type of CDM solution employed (e.g. paper 
data capture vs. eDC). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6 – CDM activities carried out over the course of a clinical study 
 
 
This section describes and discusses the activities I participated in. To better inform on the 
circumstances under which these activities took place, I present below a table that briefly 
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describes the studies I was actively involved in and which will be mentioned throughout the 
chapter (Table 2). 
 
Table 2 - Description of the clinical studies I was involved in as a Data Management Trainee 
Study Name  Study Description Type of CDM 
Solution 
Study A Phase IV, non-comparative, open-label, multicentre clinical trial in patients with 
metastatic prostate cancer 
eDC 
Study B Phase II, randomized, parallel, open-label, multicentre clinical trial in patients with 
metastatic prostate cancer 
eDC 
Study C Phase III, randomized, parallel, open-label, multicentre clinical trial in children 
aged 6-11 with acute viral and allergic rhinitis 
eDC 
Study D Phase III, randomized, parallel, open-label, multicentre clinical trial in adults with 
acute viral and allergic rhinitis 
eDC 
Study E Non-interventional, prospective, multicenter study in adult patients with chronic 
myeloid leukemia 
eDC 
Study F Phase II, single-group assignment, open-label multicentre clinical trial in women 
with ovarian, primary peritoneal or fallopian tube cancer 
eDC 
Study G Phase II, non-randomized, non-controlled, open-label, multicentre clinical trial in 
patients with metastatic colorectal cancer 
Paper CRF 
Study H Non-interventional, prospective cohort study of patients with multiple sclerosis eDC 
Study I Phase I, dose-escalation clinical trial in patients with locally advanced cervical 
cancer 
Paper CRF 
Study J Non-interventional, cross-sectional, multicenter study of patients with Type 2 
diabetes in Portugal. 
Paper CRF 
Study K Phase IV, prospective, randomized, parallel, single-blind, multicentre clinical trial 
in patients with the flu/common cold. 
eDC 
Study L Non-interventional, prospective and retrospective cohort study in patients with 
severe asthma 
eDC 
Study M Non-interventional study on the impact of patient education and on referral 
strategies of patients with rheumatoid arthritis and axial spondyloarthritis 
Paper CRF 
Study N Phase IV, randomized, crossover, open-label, multicentre clinical trial in patients 
with Chronic Obstructive Pulmonary Disorder 
Paper CRF 
Study O Non-interventional, retrospective cross-sectional study of patients with Type 2 
diabetes. 
Paper CRF 
Study P Phase IV, single group assignment, open-label clinical trial study in moderate to 
severe ulcerative colitis patients 
eDC 
Study Q Phase II, single group assignment, open-label, multicentre single arm study in 
patients with pituitary adenomas 
eDC 
Study R Non-interventional, prospective cohort study of patients with uncontrolled Type 2 
diabetes. 
Paper CRF 
Study S Non-interventional study for the assessment of the effectiveness and care 
patterns of diabetes management 
eDC 
Study T Non-interventional, cross-sectional, multicentre study of Type 2 diabetes mellitus Paper CRF 
Study U Phase IV, randomized, parallel, single-blind, multicentre clinical trial in the post-
operative period following a cesarean section. 
eDC 
Study V Phase III, randomized, parallel, single-blind, multicentre clinical trial in pre-
pubescent children with growth hormone deficiency 
eDC 
Study W Non-interventional, prospective cohort study of HIV-1 subjects in Portugal. Paper CRF 
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3.2.1 Study Setup 
In this section I will provide an overview of and discuss the various CDM activities typically carried 
out before a clinical study starts. For the purposes of this document, the start of a clinical study 
refers to the point in time in which data collection to fulfill the study’s objectives begins. 
3.2.1.1 Data Management Plan 
 
The DMP is one of the most important documents produced by the clinical data manager. It is 
written at the beginning of every new study, before any substantial data management work is 
executed, and it details how CDM is to be carried out for that study (49). The methodology and 
standards that will be followed for the purposes of data collection, processing, transfer and 
archive (53) are described and justified. 
 
It sets the focus for every CDM project, defining the work to be performed, the persons who will 
perform it and the documentation that must be produced as evidence. It has become an industry 
standard and it is generally the first document an auditor will ask for when looking into a 
company’s data management activities (49). 
 
The length, level of detail and sections of each specific plan are usually consistent within a 
company, but can vary considerably between companies.  Topics usually addressed by a DMP 
include (49): 
 CRF development and review 
 CRF completion guidelines 
 Database design 
 Database validation 
 Data entry 
 Data cleaning and query management 
 Coding procedures 
 Serious Adverse Event (SAE) reconciliation 
 Data quality control 
 Database lock 
 Data transfer 
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To avoid overwhelming staff and facilitate the process, the use of templates and previous plans is 
advised (49). During my curricular internship, the CDM team decided to implement a template for 
the DMP as a means to increase efficiencies. At the suggestion of my supervisor, I was responsible 
for preparing this template. To this end, it was important to consult with my colleagues. They 
provided with a practical insight that helped me prepare a document that met their needs 
effectively. This template is currently in force at the Data Management Sub-Unit of Eurotrials, 
Scientific Consultants. 
 
Regardless of the approach, the DMP should provide a clear understanding of what is expected 
from the data management team and serve as a data management reference tool for the entire 
project staff. This includes defining, for instances, what the study data manager expects from 
other team members (e.g. the turnaround time for query resolution) (49). 
 
Despite being a plan, the DMP is not a fixed document (53). Whenever a key process or a software 
application, for example, suffer a significant change, the DMP should be adequately revised and 
updated to reflect how, based on those changes, the data manager will be performing his or her 
tasks from that point onwards (49). 
 
In the course of my internship I never prepared a complete DMP. As mentioned above, this is one 
of the key documents of any CDM project and, as such, it is vital that the study data manager 
prepares it and knows it well. I did, however, have the chance to collaborate with the study data 
manager of Studies D, I and N in preparing the DMPs for these studies. 
 
3.2.1.2 Case Report Form Design 
 
The CRF is defined by the ICH guideline on GCP as a “printed, optical or electronic document 
designed to record all of the protocol required information to be reported to the sponsor on each 
trial subject” (4). It is arguably the most important document in a clinical study besides the 
protocol. In fact, designing a quality CRF that allows for the collection of the proper data points is 
paramount for a study’s success. Failure to collect the adequate information compromises a 
meaningful analysis of the study’s outcomes (31) rendering it useless. 
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In connection with this, it is important to note that concerns over CRF quality should be present 
upstream, since its content and structure depend heavily on the study’s protocol. A thorough 
revision of the protocol, focused on that document’s impact on CRF design, is recommended 
before proceeding to CRF production (54). CRF development may be parallel or sequential to 
protocol development (55), but the final version of the CRF should only be released after the final 
version of the protocol is available. 
 
There are two major categories of CRFs: traditional paper-based CRFs, where data is manually 
recorded by study site personnel in paper forms and later entered into a computer database by 
the CDM team; and eCRFs, founded on central web-based systems, which allow real-time data 
entry by study site personnel directly into the study database (31, 55). 
 
I had the opportunity to participate in the process of CRF design for study V. I was also involved in 
the revision of the CRF of study S prior to its implementation. When doing this, I had to take into 
consideration a number of aspects that are usually to be observed in the design of a CRF. These 
aspects can be roughly divided in three groups: 
 
A. Content  
When designing a CRF, it should be clear for the person carrying out this task what data is to be 
collected during the clinical study, so as to avoid requesting unnecessary information that does 
nothing but stagger the data collection process. The protocol typically defines what data needs to 
be collected to meet the study’s objectives and fulfill any and all regulatory requirements (54). 
 
To ensure that the information that is recorded on the CRF is the one that was expected to be 
obtained: 
 Each CRF page or record should be explicitly associated with a specific patient by the 
means of the appropriate patient unique identifier (ID) (55). 
 Questions should be clear and concise (56), so that the person recording the data neither 
misinterprets them nor provides unambiguous answers (27). The terminology employed 
throughout the forms should be well-known and only approved medical abbreviations 
should be included.  
 Questions should be phrased in the positive, to avoid confusion (56). 
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 Raw data (e.g. date of birth) should be requested instead of derived data (e.g. age). 
Derived data should be determined by a computer using raw data, to reduce the 
probability of error (54). 
 Objective assessments (e.g. enzyme test results, ECGs) should be preferred to subjective 
assessment tools, except where absolutely necessary (e.g. pain assessment scales) (54). 
 When using assessment methods that provide numerous information (e.g. X-rays, CT 
scans, etc), data collection should be focused on the presence/absence, dimensions or 
other objective characteristics of the target of interest (54). 
 When requesting the classification of an observation or event as normal or abnormal, 
these concepts should be clearly defined beforehand (54). 
 Referential and redundant questions (55) should be avoided, to prevent duplication of 
values, which is bound to generate discrepancies and confusion (49). 
 Blank fields should not be acceptable answers to any questions. Answers such as “Not 
applicable”, “Not available” or “Unknown” should be provided as part of checklists or 
accepted as answers in open text fields, as appropriate (49).  
 
When paper CRFs are used, one field that should be duplicated in all CRF pages is the header. It 
should contain fields for entering each site’s and patient’s unique ID, at a minimum. Having the 
header in every CRF page and consistently writing the applicable unique IDs ensure that, in case 
any pages are misplaced, these can be linked to a given patient (27) and no data is lost. 
 
B. Presentation 
The choice of layout, question style and other elements of CRF presentation are critical for data 
collection. When designing a CRF, the point of view of the person who is going to use it to record 
the study data should be taken into account. One of the goals should be to produce a CRF that 
causes as little trouble as possible to that person. The easier it is to navigate through and fill in the 
CFR, the higher are the chances of obtaining data that is of high quality and meets the needs of 
the study.  
 
Consequently: 
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 Questions should be presented in a logical order, ensuring that the data flow makes sense 
from the perspective of the person completing the forms (55). Related questions should 
be grouped in the same module (57).  
 The style of the CRF should be consistent throughout (55). 
 Date and time formats should not only be compatible with the database, but also familiar 
to the person filling in the CRF (54). 
 Units or a list of units that the study site personnel completing the form can choose from 
should be provided. This ensures that recorded values are comparable (57).  
 Leaded or open-ended questions (57) should be avoided, except where the answer to the 
question cannot be predicted (54). Where open-text fields must be used, their length 
must be limited to the length of the type of answer that is expected (12). Long text fields 
can impact database design and illegible handwritten text fields (in the case of paper 
CRFs) can seriously impair data entry downstream (49). 
 Closed questions should be preferred when there is a known, limited list of possible 
answers. This not only reduces the chance of error, but helps clarifying the purpose of the 
question for the person filling in the form (54). 
 When all of the possible answers for a question are not known, the solution is to employ 
combined questions. Combined questions are multiple choice questions with a final 
option associated with an open text field (54). 
 
C. Methodology 
Reducing problems that CRF fillers have with the forms is one of the challenges of CRF design. 
Care must be taken when selecting the type size, type face, case, line length, spacing and graphics 
to ensure readability (54). Using bold, italics or different fonts can be helpful to highlight certain 
important notes or warnings, but should be done so moderately.  
 
It is also important to avoid cluttering CRF pages with an amount of information that might impair 
its intelligibility (57). To avoid such cluttering, attention should be paid to CRF organization. It is 
preferable to have more pages, each with a small of amount of data, than a small number of 
pages flooded with questions. Following the very important principle of collecting only the data 
needed to satisfy the objectives of the protocol also helps in fulfilling this goal (12).  
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The use of standardized formats to collect data is also highly recommended (13), and this benefits 
both the form filler and the CDM team. This is because standard formats usually mean that 
completion instructions, database design, edit checks and data analysis will vary minimally 
between projects (49). 
 
The importance of designing a CRF suitable for completion by study site personnel is 
unquestionable, but CRF design should also be carried out with data processing and data analysis 
(13) in mind. For instances: diagrams, such as a representation of the human body where the 
investigator marks the affected areas, are recognizably difficult to quantify and analyze; analog 
scales, often used as an indication of a patient’s level of pain, require a lot of work to be 
accurately transcribed into a database. Although modern electronic solutions are a good 
alternative to these specific manual data collection tools, the latter are frequently preferred to 
the former (49) and the difficulties remain.  
 
The involvement of a cross-functional team in CRF design is the best way to ensure that the data 
collection tool that will be used is clear and easy to fill in by the study site personnel, efficient for 
processing by the CDM team and appropriate for subsequent analysis by the statistician (49).  
Having an SOP in place for CRF design is recommended to help managing this industrious process. 
 
In the case of the CRF designed for study V, a thorough review was performed by a Medical 
Writer, a member of the monitoring team and members from the client’s team, including 
Pharmacovigilance personnel, to ensure the final CRF met all needs and expectations. 
 
The final product of the CRF design process is the CRF Matrix or sample CRF. The CRF Matrix is a 
document containing every unique CRF page for the study. For studies with multiple patient visits, 
the CRF Matrix specifies what modules are to appear in the CRF pages of each visit.  
 
3.2.1.2.1 Comparison of Paper-based and Electronic Data Capture Tools 
 
The above recommendations are applicable to both paper CRFs and eCRFs. However, the design 
of eCRFs is associated with certain specificities inherent to the computerized environment in 
which they reside. One such thing is the need to design data entry screens that are intuitive and 
user-friendly. This is generally achieved by making data entry screens as similar as possible to 
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paper forms. There are also functionalities that facilitate the data entry process, such as 
displaying a form depending on the answer to a given question (27). But, as I had the chance to 
learn during my curricular internship, the differences between paper-based and electronic data 
collection tools do not stop here. 
 
Historically, the data collection process at study sites has been mainly manual. Investigators, or 
their designees, transcribe data (source data) from hospital records to CRFs. Clinical Research 
Associates (CRA) visit the study sites to verify that the recorded data match the source 
documentation in a process known as Source Document Verification (SDV). The verified CRFs are 
then collected and sent to the CDM team (58). For each shipment between the CRA and the CDM 
team, a Transmittal Form (TF) detailing the contents of the shipment is prepared. 
 
After assessing the CRFs for any discrepancies, the CDM team follows up with the CRA to issue the 
necessary queries, via a specific form known as Data Clarification Form (DCF). Once all queries 
have been resolved, data entry into the study database can begin and only after completion of 
data entry can data validation commence (58). 
 
This process is obviously burdensome and time consuming. It is partially accountable for the long 
duration of most clinical trials and, ultimately, compromises the time for a drug to come to 
market (58). These problems, coupled with recent technological advancements and the 
considerable price reductions in computer equipment, have raised the interest in real-time data 
management (59) as achieved with the use of eDC systems.  
 
The vast majority of modern eDC systems operates online and possesses various characteristics 
that facilitate the job of the multidisciplinary clinical study teams, including, but not limited to 
(49): 
 Single field and cross-field checks for data validation. 
 Tools to allow investigators to review and resolve data discrepancies. 
 Tools to allow CRAs and clinical data managers to manually raise queries while reviewing 
data. 
 Electronic investigator signatures. 
 Ability to lock the data at the end of a study. 
 Tools to issue a variety of reports on patient- and site-related data. 
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 Ability to export data for review and analysis in various types of files. 
 
The use of electronic means allows real-time delivery of clinical trial data to the CDM team by 
study sites (49), which represents an increment in efficiency in comparison with the process 
intermediated by CRAs as described above. The CDM team can implement online data validation 
checks to better control the quality of data at the point of entry, as well as perform real-time data 
manual data validation (59). This makes the site quickly aware of problems that can be addressed 
on the spot and are less likely to be replicated in subsequent patients (49).  
 
When looking at some numbers, the case for eDC is better understood. For a traditional paper 
based study, it can take up to one week or more to obtain an answer to a query and the 
associated cost can be of US $80-120 per DCF sent to the site. With eDC, a query can be available 
to the site/investigator and solved in a matter of hours. Clearly this is much more time- and cost-
effective. The growing implementation of eDC has resulted in other important reductions, such as 
in paper consumption, in CRAs’ workload, in the risk of loss or damage of CRFs during transit and 
in courier costs associated with CRF and DCF shipping (58).  
 
Nevertheless, eDC systems present with some obstacles that require proper attention. First and 
foremost, compliance with the applicable regulatory norms like FDA’s 21 CFR Part 11. This 
includes, for instances, being capable of preventing unauthorized accesses to data, having inbuilt 
features to detect and keep control on fraudulent data (e.g. audit trails) and incorporating 
electronic signatures (58).  
 
Moreover, the systems must accommodate to the characteristics of data generation, processing 
and maintenance, which are not the same as when traditional paper-based data collection tools 
are used. Examples of such characteristics include (58): 
 Data entry is not a responsibility of the CDM team, but of the study site personnel. 
 Data review and validation by the CRA and by the CDM team take place in the same 
environment. 
 A training environment must exist, so that all teams involved in the study can be trained 
on the system prior to study start.  
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 Need for an IT support functionality, so that system users can obtain help to solve any 
technical issues. This support is expected to be available at all times, as many studies 
involve sites and/or personnel from across the planet. 
Shifting the responsibility of data entry to investigational site personnel constitutes a difficulty in 
itself (58). The task is often dubbed a tough or tedious one and the possibility of errors is much 
the same as the one in paper data capture because the core procedure (transcription of data from 
patient medical records to the CRF) remains manual (26). Other major challenge for eDC is the 
possibility of disruption of data due to inadequate human operation of the software or 
inadequate maintenance of the system by the responsible personnel. It is also necessary to have 
suitable infrastructures for storage and maintenance of data in a repository where it can be made 
readily available (59). Study sites need to possess computers that can reliably connect to the 
internet – otherwise, access to the eDC will be compromised (49). Depending on the system, 
programming skills might be necessary to develop the database and operate the software (59). 
 
The workflow for the conduct of the CDM activities throughout the study will necessarily change 
with the use of an EDC application. The same CDM tasks will have to be performed, but there is a 
degree of temporal flexibility that does not occur when a paper trail exists. The nearly immediate 
availability of data at all times gives it great volatility, in that it can be entered, changed, reviewed 
and monitored within very short periods of time. Naturally, this requires companies and centers 
to adjust and separate SOPs might exist for paper-based and EDC-based studies.  
 
All in all, eDC can improve efficiencies and speed up the decision making process when compared 
with the paper-based data collection tools (58), provided the system is well designed, carefully 
introduced and work processes are adjusted to it (59). However, some challenges exist as 
stakeholders debate on the costs associated with the use of technology and the potentially 
associated steep learning curve for clinical research teams. 
 
3.2.1.2.1 Case Report Form Completion Guidelines 
 
According to my short but very rich experience,  it is impossible to eliminate the chance of errors 
when it comes to filling out CRFs, no matter how well designed they are (13). CRF completion 
guidelines are a study-specific document prepared to assist the investigator and/or other study 
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site personnel in completing the CRF. Its goal is to help ensuring accurate completion of all 
required data fields and enhance data flow (60), thereby reducing the probability of error.  
 
It should provide step by step, clear instructions on how to complete all required fields in a logical 
manner, including study and data field specific expectations (31). This guide should also specify 
the measures to be adopted by the personnel filling in the forms in case data are wrongly entered 
and in cases of unknown data. Much like the CRF itself, CRF completion guidelines should be 
simple, concise and easy to understand (60). 
 
CRF completion guidelines may exist in various formats. For paper CRFs, they can be printed as 
part of the CRF or as a separate document. For eCRFs, they are usually prepared as a separate 
document that the monitoring team distributes to the sites. They may also be complemented by 
direct instructions provided on the eCRF screens or by system prompts or dialogs that appear in 
accordance with the data that are entered (31). 
 
I was responsible for preparing CRF completion guidelines for study E. It is worth noting that, 
since eDC was used for this study, it was important to include print screens of the system and 
other cues to clarify the instructions provided in text form. 
 
3.2.2 Database Design and Validation 
 
After data has been captured, be it on paper or through an eDC system, it must be stored in a 
database that underlies the CDMS that will allow the clinical data manager to conduct the 
procedures that comprise data processing. There are several types of databases that can be used 
for this purpose, from Microsoft Access applications to relational applications such as Oracle® 
(49). Since the success of a study is strongly dependent on the quality and integrity of its database 
(61), it is safe to say that database design is one of the most important activities of the CDM team. 
 
The definition of the data collection tools influences, for most systems, the design of the 
database, and so the latter normally takes place after the data capture instruments have been 
defined and an Annotated CRF has been created (49). The Annotated CRF is a blank CRF (usually 
its Matrix) with annotations that connect each data point in the form with its corresponding 
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dataset name. It essentially informs where the data collected in each field is stored in the 
database (55). During the course of my internship, I was responsible for preparing the Annotated 
CRF for studies B, I, N and L. 
 
The main goal of database design is to ensure data is stored accurately, while balancing various 
needs, preferences and limitations, such as (49): 
 Clarity, ease and speed of data entry 
 Efficient creation of datasets for analysis by the statisticians 
 Future data transfer 
 Database application software requirements 
 
A poorly designed database can originate inefficiencies in data entry, cleaning, extraction and 
storage (27). A high quality database is one that circumvents these issues while meeting both 
study and regulatory requirements (61).  
 
Based on the annotated CRF, the data manager creates all pages, tables, modules and fields 
necessary to ensure that all data collected by the CRF is properly entered into and archived in the 
database. This process includes defining the length and nature (numeric or open text) of each 
field, developing codelists, defining the key or identifier fields for repeating pages and specifying 
auto-calculated fields. Depending on the system, the data manager might have to build the data 
entry screens based on the created fields, but certain systems create those screens automatically 
(57). 
 
Designing a database was one of the most challenging activities I developed during this internship. 
I had the opportunity to use different tools (systems), with varying degrees of complexity. 
Specifically, I was involved in designing the database for studies I, N and Q. 
 
3.2.2.1 Data Validation Checks 
 
Data validation checks are manual and computerized checks performed on clinical study data with 
the aim of identifying any inconsistencies (discrepancies) and potential errors that require 
rectification. Data validation checks can be manual or automatic (i.e. computerized checks that 
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automatically identify the inconsistency and alert the user of its existence) (55). The definition of 
manual and automatic checks, including the programming of the latter, is an integral part of 
database development (13). Data validation checks are specified in a document known as Data 
Validation Plan (DVP). It consists of a table describing the details of each check, namely: the CRF 
page and module or table where it will be applied; the logic of the check; its classification as an 
automatic or manual check; the message that is to appear when the check finds a discrepancy 
(49).  
 
While I did not prepare a full DVP myself, I had the chance to collaborate with the study data 
manager of study E in developing the DVP for this study. This, in itself, was an excellent way to get 
introduced to the ins and outs of this particularly elaborated task. 
 
Edit checks commonly fall under one of the following categories (49): 
 Missing values 
 Range checks (e.g. heart beat must be between 60-100 bpm) 
 Logical inconsistencies (e.g. patient is male but potential for pregnancy is indicated) 
 Checks across modules (e.g. reason given for study discontinuation is Adverse Event, but 
no Adverse Event is recorded with action taken being study discontinuation) 
 Checks for protocol violations (e.g. exam date should be the same as visit date, but it is 
not) 
In studies where paper CRFs are used, automatic checks at the point of entry are not very 
commonly applied. Instead, data is reviewed for inconsistencies: at first, manually by data entry 
staff while going over the CRF (e.g. missing patient IDs that prevent entry of full pages); after all 
data has been entered, the data manager runs the manual and automatic edit checks as specified 
in the DVP. In studies where eCRFs are used, and because most eDC systems already allow for 
that, automatic checks are fired at the point of entry and manual checks are run later on by the 
data manager (49).  
 
The amount of checks done electronically will depend on the capabilities of the system, on the 
method of data collection and on the particularities of the study protocol. It is recommended that 
the computer be used to do as many checks as possible for efficiency reasons (27). 
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Systems external to the data management application can also be used to check data for 
discrepancies. This happens when the CDMS is unable to support checks across patient records, 
visits and/or pages. External, standalone programs are used to run the automatic checks against 
the database after data entry (27).  
 
Inconsistencies found in either paper CRFs or eCRFs are sent to the investigator as queries for 
resolution. The process for generating, answering, assessing and closing queries is known as 
Query or Discrepancy Management and it will be discussed later.  
 
3.2.2.2 Database and Data Validation Plan Validation 
 
Upon completion of the database design process, the database must be validated. This includes 
an assessment of its structure and of field-specific definitions, of the automatic edit checks and of 
the system’s audit trail to confirm that everything works as expected (62). 
 
For the purpose of database validation, test subjects are created in the system (55). Dummy data 
is entered for every field and the data manager must verify that (38, 56): 
 Each field on the data entry interface is correctly mapped to its corresponding database 
field. It may be necessary to review output data listings from the database to make sure 
this occurs (31).  
 The data field definitions are as expected in terms of length and type. 
 Primary key fields are assigned correctly and no duplicates are produced. 
 The audit trail is working as expected, providing date, time and user stamps whenever a 
record is created, modified or eliminated. 
 That data uploads, exports and integrations are functioning properly. 
Simultaneously, the data manager must test that the automatic edit checks set up for the study 
are triggered under the expected circumstances. To this end, test data should be created for all 
automatic checks and every check must “pass” and “fail” this test at least once (55). This means 
that proper data (e.g. a blood pressure value that falls under the normal range) should be entered 
to ensure that the check is not triggered when the information is correct, and wrong data (e.g. a 
blood pressure value that does not fall under the normal range) should be entered to confirm that 
the edit check is triggered. I was involved in this process for studies C, E, H and P.  
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The output of this validation is a Database Functionality Report (DFR).  This document, prepared 
by the data manager, contains the results of the validation, including any errors that were found 
and the actions taken to correct them. 
 
Database and DVP testing occur in a secure, test environment. Only when a database has been 
reviewed and fully tested will it be set in “production” or sent to “go live” status. Any changes in 
structure or programming during the conduct of the clinical study will also be performed and 
tested in a “test environment” before being made effective in “production environment” (55). 
Changes to the database that are performed after the clinical study has begun are known as mid-
study updates. Regardless of the extent of the alterations, a complete validation procedure has to 
be carried out and a new DFR is produced. 
 
Changes during the conduct of the study are much more complicated when an eDC application is 
used, compared to when a paper CRF (associated with an in-house database) is used. 
Modifications must be made carefully and must be made available to all study sites at the same 
time. This must be done so to prevent system failures that compromise patient enrollment, 
medication dispensing and other study procedures (49). 
 
Another important difference is worth mentioning at this point. In studies conducted on paper 
CRFs, database design and validation can lag considerably behind patient enrollment because the 
database will only be needed once CRFs have been completed and sent to the CDM team for data 
entry. When eDC systems are used, no patients can be enrolled until the entire application has 
been built, tested and approved. Therefore, establishing realistic but practical timelines for having 
an eDC application ready for enrollment is critical and may significantly impact the project (49). 
 
3.2.2.3 Database access and users training 
 
Several regulatory documents, including FDA’s 21 CFR Part 11 and ICH’s guideline on GCP, clearly 
define the need to limit access to the CDMS to authorized personnel by way of controlled log-in 
IDs (with passwords) and database security restrictions (27). For each study, it is the data 
manager that holds the responsibilities of account management (i.e. determine who is assigned 
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an account to enter the system) and access control (i.e. define how each user is given access to 
particular features of the system) (49).  
 
Each authorized member of the study staff is provided with a valid user ID and password to access 
the application. In eDC studies, access is extended to study site investigators and/or study 
coordinators, who will be responsible for data entry and to CRAs in charge of the study’s 
monitoring activities (63). It is important to guarantee that each account name is unique and that 
passwords are not easily guessed and are changed on a regular basis (27). Every exclusive 
combination of user ID and password allows the system to associate a particular person to any 
changes, additions or deletions made to records stored in the database via its audit trail 
functionality (49). 
 
The definition of users’ permissions in the CDMS is dependent upon their role in the study. As 
such, there can be a “Data Entry” role, an “Investigator” role, a “Data Manager” role, and so on. 
Access rights can be further specified at the study level, thus ensuring that an individual with an 
“Investigator” role can only perform that job in his particular project (49). For multicenter studies, 
permissions can be additionally narrowed at the site level by ensuring, for instances, that 
investigators cannot access any data but those relative to their patients (27).  
 
The study data manager must keep a log documenting the persons authorized to access the 
CDMS, the permissions attributed to each user and the dates when those permissions where 
assigned and revoked (49). These users should be trained on the system prior to study 
commencement and before any accesses are granted (27). For eDC, this training complements the 
CRF Completion Guidelines described before. 
 
I did not have the chance to put the knowledge I obtained on these tasks into practice. 
Nevertheless, the explanations and demonstrations provided by my colleagues on how these 
procedures unfold were vital to fully understand them. 
 
3.2.3 Data Processing 
 
In this section I will provide an overview of and discuss the various CDM activities typically carried 
out throughout the course of a clinical study. 
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3.2.3.1 Data Entry and Related Activities 
 
Data entry-related activities refers to a sequence of activities that are characteristic of paper-
based clinical studies, where CRFs are completed by study site personnel and data is entered into 
the database at a later stage by members of the CDM team. These activities can be divided into: 
pre-data entry activities, receipt and tracking of CRFs, data entry and data cleaning. 
 
3.2.3.1.1 Pre-Data Entry Activities 
 
Before study data entry begins, data entry operators (DEO) must receive the appropriate training. 
This training is usually given by the data manager responsible for the study and covers (64):  
 Information on the computer equipment that will be used for data entry and on the 
credentials necessary to access it. 
 The dynamics of the system where the data entry activities will be carried out. 
 Specific instructions on the data entry process itself, namely:  
› How to fill in each specific field 
› What to do if a field is blank or if information for a field is said to be unavailable. 
Usually there are specific codes that can be entered in these cases. 
› General rules to be observed during the data entry process. 
This face-to-face training is supplemented by a set of Data Entry Guidelines, which detail the 
instructions to enter data and are provided for use throughout the process (57).  
 
3.2.3.1.1 Receipt and tracking of Case Report Forms 
 
The procedure by which CRF receipt is performed, acknowledged and data is made available for 
processing by the CDM team must be sufficiently detailed in the appropriate documentation. It is 
imperative that the origin and destiny of data is known beyond doubt throughout the study (31). 
The primary goal of using a tracking method is to ensure that no data is lost and that all data 
makes it into the study database (49).   
Before a study begins, blank CRFs and their respective completion guidelines are shipped to each 
study site. As the study progresses, completed CRFs or completed CRF visits are forwarded by the 
CRA to the CDM team after they have been reviewed. Each batch of CRFs sent by the CRA are 
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accompanied by a TF. In each TF the page numbers or other unique identifiers of the CRFs are 
recorded as evidence that those CRF pages have been shipped from the site to the CDM team.  
 
Upon receipt, all CRFs are cross-referenced against the corresponding TF. Discrepancies between 
the contents of the shipment and the information on the form are flagged and clarified with the 
study’s CRA. Common discrepancies that result from TF and CRF review include (49): 
 Different CRF pages with the same page number 
 Pages with no data 
 Duplicate pages 
 Pages with no page number 
If necessary, the study site must be contacted to obtain clarification, but most circumstances can 
be resolved by the CRA. 
 
TF review was one of the first tasks I was assigned during my curricular internship. Throughout its 
course, I participated in CRF receipt and tracking for studies G, J, M, R, O and T. 
 
3.2.3.1.1 Data Entry and Data Cleaning 
 
Following receipt of data from the study site, data are entered into the clinical study database. 
The two most common methods for this are single data entry and double data entry.  
 
In double data entry, data is entered twice, but separately, by two DEOs (65). During data entry, is 
not uncommon for errors to occur. These lead to the introduction of wrong values into the 
database, which can potentially impact the final analysis of study data (27). The second pass entry 
in double data entry helps identifying issues in data caused by transcription errors and illegible 
data (65). Usually, validation checks at the point of entry are not incorporated into the 
application, as they would only slow down the DEOs’ work (49). 
 
After both DEOs have entered all study data into the database, the two entries have to be 
reconciled. This is known as data cleaning and can be achieved using one of two approaches. One 
alternative is for the CDMS to automatically compare the two entries and identify the 
inconsistencies between them. These are then manually corrected by a third person, typically the 
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study data manager, who reviews the report of discrepancies.  For a proper correction of the 
value, this person checks the relevant CRF to ascertain which value is right or if data really is 
illegible on the form (54). One other alternative involves using an immediate check at the time the 
second DEO is re-entering the data. Whenever a difference between values is detected by the 
system at the point of entry, the DEO is informed and must make a decision on what is the correct 
value. Once more, review of the forms is necessary (27). 
 
The rationale for employing double data entry is that the resulting high accuracy justifies the 
additional expenses and time delays that this method originates (54). Nevertheless, some 
simulation studies have shown that the gains in data quality from double data entry may actually 
not substantiate its efficiency, since the process of data entry and subsequent review is very time- 
and budget-consuming. Regardless, it is the most used method for data entry in paper-based 
clinical studies. 
 
During my training, I was never involved in double data entry activities nor did I actively 
participate in data cleaning activities following double data entry. However, I was able to 
understand the practical aspects of these activities by observing my colleagues’ work and 
inquiring on specific aspects of the procedures they adopted. 
 
In single data entry, data is entered into the database only once by a DEO (57). The accuracy of 
data entered using this method is typically deemed inferior to that of data entered via double 
data entry (65). Therefore, single data entry should be an option when there are detailed checking 
routines built into the data entry application, as well as checks that are run after entry (49). 
However, as I learnt during my internship, this is not always the case. Other concerns, such as 
time and cost, can favour the use of single data entry by some study sponsors.  I had the 
opportunity to perform various single data entry activities, specifically for studies G, M and O. 
 
Irrespective of the data entry method employed, a log documenting which CRF pages have 
already been entered and which have not yet been entered should be maintained. 
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3.2.3.2 Data Validation 
 
Data validation is the process of assessing the validity of trial data to ensure that the study 
database attains a reasonable level of quality (65). By the end of the data validation procedures, 
the study database is expected to be accurate, consistent and a trustworthy representation of 
what happened to every study participant at the study site(s). Data validation by the CDM team is 
an integral part of ensuring GCP-compliant data and it is absolutely vital to the delivery of high-
quality data for statistical analyses and reporting (54). 
 
Regardless of the data capture instrument used, errors are bound to happen when collecting and 
entering data into the database (66). As described in Section 3.1.3.1, prior to study start, the study 
data manager creates a DVP establishing the manual and automatic checks that will be performed 
to identify any errors or inconsistencies (discrepancies) in study data. It is at the Data Validation 
stage that the DVP comes into action. 
 
The points in time in which DVPs are put into effect differ slightly between paper-based and eDC-
based clinical studies. In paper-based studies, data validation occurs when all CRFs have been 
received by the CDM team and entered into the database. Several months, and even years, may 
elapse between the date of data collection and the date of data validation. I participated in the 
validation of two paper-based studies (G and I), where the interval between data entry and data 
validation was indeed very pronounced. 
 
In eDC-based studies, however, the vast majority of systems allow data validation to take place on 
an ongoing basis. Automatic checks operate alongside data entry at the study site, alerting for the 
presence of discrepancies throughout the patient participation period. Manual checks or manual 
reviews of data can be either performed at regular intervals throughout the study (such as those I 
participated in for studies A and F) or simply close to the study’s end (65). 
 
One type of manual review that brings added value when done after a significant amount of data 
is available is the listing review. In fact, the listing reviews I was involved in, for study U, occurred 
close to database lock. The goal of listing reviews is to detect unusual or questionable values that 
stand out among the remaining data but that might otherwise pass all implemented validation 
procedures (49). This may range from simply identifying nonsensical phrases or numeric values 
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(outliers) to reviewing medication records for drug prescriptions that are not permitted by the 
protocol.   
 
As mentioned in Section 4.1.3.1, edit checks can be run in the CDMS itself or by means of an 
external application. During the course of my training, I had the chance to apply both 
methodologies for data validation. Data validation for studies A, F, G and U was performed using 
the CDMS in which they were included. Due to the limitations of its CDMS, however, study I was 
validated using an external application that allowed the database to be queried and assessed by 
means of a specific programming language. 
 
Whenever a discrepancy is detected, through any of the above methods, a query is generated and 
issued to the corresponding investigator’s site for resolution (65). The specific process for 
managing discrepancies is detailed in the following section. 
 
3.2.3.2.1 Discrepancy Management 
 
Discrepancy management refers to the steps taken by the data manager to generate queries, to 
evaluate the responses given by study investigators to those queries and to close them as 
resolved or irresolvable. Queries must be handled with the utmost attention, since they are a 
critical part of database validation (65). The ways in which a discrepancy is managed are 
contingent upon the data collection tool employed, as briefly discussed in Section 3.1.2.1. 
 
For paper-based studies, like Study I, DCFs are sent to the study site requesting clarification of all 
discrepancies that have been found after the predefined checks are run (65). A DCF is generated 
per study subject for whom one or more discrepancies require clarification by the investigator. 
The forms are produced based on an existing template consisting of study site and patient unique 
identifiers, the date when the queries were raised and a table where all discrepancies are 
described. Each discrepancy is also associated with a unique ID code, which is assigned by the 
data manager. This unique ID code helps tracking queries that were sent and answers that are 
received. The DFCs also include a field for investigators to write, sign and date the answer to each 
query. 
 
The CDM team forwards the DCFs to the CRA, who delivers them to the corresponding study sites.  
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After the DCFs have been completed by the investigators, the CRA returns them to the data 
manager, who will update the database with the provided resolutions (65). Nonetheless, a site’s 
response to a  query may not necessarily result in a change to the data. The original value may 
really be as reported on the CRF or it may not be possible to obtain a missing value. It is also 
important to note that responses on query forms must be treated by both the site and the 
sponsor just as CRFs, because they contain original site data (49). Modifications to study data that 
do not originate from a DCF are not permitted (27). 
 
Exceptionally, discrepancies can be resolved in-house. This is done by employing Self-Evident 
Corrections (SEC), whereby data managers are allowed to correct a restricted set of study-specific, 
predefined inconsistencies without sending DCFs to the study sites. The use of this method must 
be agreed upon with the sponsor beforehand and it is not at all common (49). Indeed, it was 
never performed during my time as trainee at the Data Management Sub-Unit of Eurotrials and, 
therefore, I cannot provide a personal account of how it is put into practice. 
 
Discrepancy management is undoubtedly more simple and efficient in eDC-based studies, as I 
learned from working in study A. Automatic checks, which are directly programmed into the 
system, trigger the queries simultaneously to the submission of data that does not comply with 
the consistency rules established in the DVP. Query texts do not reach the investigator via a 
separate form, but through the eDC system’s interface. The texts will inform the investigator that 
the value is missing, out of range or not logical according to the protocol or previously recorded 
information and request that the correct information be provided (27).  
 
Queries resulting from manual checks are managed more or less the same way. The only 
difference lies in how they are generated. In this case, they have to be manually created by the 
data manager after a review of the data reveals the presence of an inconsistency. However, the 
process is faster than filling in a paper form and answers can also be obtained in a matter of 
hours. This contrasts with the many days (or even weeks) that the data manager has to wait for a 
query resolution in paper-based studies. 
 
Another advantage provided by CDMSs associated with eDC is the inbuilt capacity to record, track 
and store discrepancies and their resolutions with an audit trail as stipulated by the ICH guideline 
on GCP (49). Permanent records of changes to the study database, which are no more than a 
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representation of a dialogue between investigator, CRA and data manager, are created 
automatically, eliminating the need to produce more documentation. 
 
Irrespective of the method used to generate queries to study sites, one thing that I have learned is 
that data managers must be careful when requesting clarifications to study data. Messages sent 
via DCF or appearing directly in the screen used for data entry must be clear, but should not be 
leading, i.e., they should not incite the investigator to provide a particular answer (49).  
 
Ideally, for every discrepancy that is found, one query should suffice to obtain a satisfactory 
resolution. Yet, this is not always the case. More often than not, a query must be resubmitted to 
get a clarification on the first resolution. The whole process can be repeated as many times as 
needed until an adequate response is given (49).  
 
3.2.3.3 Data Standardization 
 
Data standardization is the process of introducing consistency in open-text fields that are not 
subject to Medical Coding, as per the sponsor’s request or authorization. The goal of this task is to 
facilitate the grouping of analogous terms for review and analysis, thus avoiding unnecessary 
replication of data (49). 
 
At Eurotrials, data standardization is performed for both paper-based and eDC-based studies. I 
was handed this task for studies G and W. This involved correcting spelling errors, removing 
nonessential information (e.g. investigator reported both the active substance and the brand 
name of a medicinal product and only the former is required for analysis), as well as any 
modifications necessary to ensure uniformity across a given data field (e.g. guaranteeing that all 
combination medicinal products are described as A + B, instead of having some as A + B and 
others as A/B). 
 
Data standardization is performed without replacing original data. For every data field that is 
planned to be standardized, an additional data field is created for the purpose of entering the 
standardized data.  After the process is complete for all predefined data fields, the database is 
said to be standardized. 
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3.2.3.4 Medical Coding 
 
In clinical studies, it is not uncommon for a huge volume of data to be produced, recorded and 
stored. Such data will then be retrieved, analyzed and presented in a variety of formats depending 
on the objectives of the study and the goals of the sponsor. For example: adverse event data may 
have to be transmitted to regulatory authorities during the course of the study to meet legal 
requirements; summaries of study data may need to be put together to create the Summary of 
Product Characteristics (SmPC); listings of safety and efficacy data obtained in clinical trials will 
probably serve as the basis of a product’s marketing authorization application.; and more (54). 
 
For such a volume of data to be summarized and fulfill its purposes, it must be countable and, to 
be countable, values must belong to the same category. Data collected via numeric fields does not 
present any problems from the outset. Text data, however, are almost always impossible to 
summarize as they cannot be relied upon to be identical (57). It is the rule, rather than the 
exception, for an event to be reported differently across study sites or even within a study site 
with multiple investigators. This lack of consistency poses many difficulties when analyzing and 
reporting data (31). 
 
Medical coding is the process whereby clinical terms reported throughout the course of a clinical 
study are standardized using regulatory-approved medical terminologies (54). Coding involves 
assigning standard numbers or terms as per the rules of the applicable coding dictionary to each 
term as it was reported by the study site (57). 
 
Fields that are usually coded include medical events reported in Medical History and Adverse 
Events tables, as well as pharmaceutical active substances reported in Concomitant Medication 
tables. It is also possible to code other data, depending on what the planned study analyses call 
for (57).  
 
There are various dictionaries available for the coding of medical terms. They can be classified in 
two groups (57):  
 Dictionaries for the coding of medical events, covering diseases, conditions and/or 
surgical procedures. This includes MedDRA, the World Health Organization-Adverse 
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Reactions Terminology (WHO-ART) and the Coding Symbols for a Thesaurus of Adverse 
Reaction Terms (COSTART). 
 Dictionaries for the coding of medications. This includes the WHO Collaborating Centre 
for Drug Statistics Methodology’s Anatomical Therapeutic Chemical/Defined Daily Dose 
(ATC/DDD) Index and the Uppsala Monitoring Centre’s WHO – Drug Dictionary Enhanced 
(WHO-DDE). 
 
The choice of dictionary will depend upon the planned analysis, the sponsor’s preference and 
even regulatory demands. For instance, European authorities require data to be coded to 
MedDRA standards, whereas Brazil’s regulatory authority accepts data coded to either WHO-ART 
or MedDRA standards. Eurotrials uses mostly MedDRA for the coding of medical events and 
WHO’s ATC/DDD Index for the coding of medications. Therefore, it was with these dictionaries 
that I had the opportunity to perform various coding tasks. 
 
Medical coding can be performed manually or automatically. Manual code allocation involves 
actively searching for the correct code in the appropriate dictionary for each of the terms and 
then manually entering those codes into the study database. Manual medical coding using 
MedDRA and the ATC/DDD Index comprised my whole medical coding experience, having done so 
for studies D, I, K and U. To successfully complete these tasks, the formal training, input and 
advice from company colleagues experienced in manual medical coding were essential. 
 
Carrying out automatic medical coding is dependent on the availability of an integrated (i.e. that is 
a part of the CDMS) or stand-alone auto-encoder. Auto-encoders make a direct comparison 
between the dictionary and the contents of one or more CRF fields predefined by the data 
manager. When a match is found, the system automatically allocates the correspondent 
dictionary term and/or code to that field. All terms for which the system cannot find a match are 
signaled and must be manually evaluated by the data manager (57). Although manual coding is 
important to acquire an in-depth understanding of a dictionary’s structure and hierarchy rules, in 
the face of a large number of records an auto-encoder can prove to be a valuable tool in terms of 
efficiency (31).  
 
Since the terms to be coded are collected on open text fields, the chances of coming across 
misspelled, vague or ambiguous terms are relatively high. Another common problem is the 
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reporting of multiple events in a single record. All these issues prevent proper code allocation and 
require clarification from study sites (57). Requests for clarification of terms to be coded or for 
splitting of a record are directed to the site as queries. The mechanism for generating and solving 
coding queries is exactly the same as the one used for any other discrepancies found on study 
data (see Section 3.2.2.1). 
 
The frequency with which medical coding is carried out varies from study to study. For instance, 
Study D was a fairly simple study with a participation period of one week and so coding was only 
performed prior to database lock, when all patients had finished their participation in the study. 
Study A, on the other hand, was a lengthy and complex study, which yielded large amounts of 
data. Therefore, coding was performed on an ongoing basis. 
 
Coding dictionaries are updated on a regular basis. New versions of MedDRA, for example, are 
released twice a year (49).  It is important that the dictionary and version used for a given project, 
for each coding stage within a given project (in case of ongoing medical coding) and for each 
dataset are documented (31). For long studies with ongoing medical coding, like Study A, it may 
happen that multiple versions of a dictionary are released throughout the lifetime of the study. 
Instructions should be in place to ensure that the person responsible for the coding of medical 
terms for those studies: evaluates the extent of changes between versions; assesses the impact of 
those changes on terms that have already been coded; and makes the necessary modifications to 
the coding of those terms (31).  
 
Quality Control (QC) of the list of standard terms and/or allocated codes takes place after medical 
coding is concluded, including for those terms which required clarification via query emission.  
This is ideally done by a person other than the one who did the coding itself (where manual 
coding was performed) and involves comparing the terms and/or codes allocated to a sample of 
the coded terms with the applicable dictionary. The goal is to verify if the coder complied with the 
dictionary’s guidelines for code selection consistently throughout the medical coding process.  
 
In studies where manual coding is performed, and after the standard terms and/or codes are 
entered into the study database, a QC of the data entry activity should also be undertaken. The 
final list of standard terms and/or codes, as produced by the coder, is directly compared with the 
terms and/or codes that were entered, in order to evaluate the presence of transcription errors. 
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The errors found in either stage of the QC process and the actions carried out to correct them 
should be properly documented.  
 
3.2.3.4.1 Standard Operating Procedure for Medical Coding 
 
During my curricular internship, the CDM team identified the need for a standardized procedure 
to carry out all of the sub-unit’s medical coding activities. In view of this need, I was challenged by 
my supervisor to prepare an SOP for the processes of medical coding of both drug terms and 
medical terms. 
 
The writing of this SOP was a very interesting task. Since I had never had the opportunity to write 
an SOP before, several questions arose during the preparation of this document. However, due to 
the theoretical knowledge I hold on SOP writing and on medical coding, complemented with the 
practical insight provided by my colleagues at the sub-unit and with the research I performed, I 
was able to successfully complete this document. This SOP, and two associated templates, is now 
in force at Eurotrials. 
 
3.2.3.5 Serious Adverse Event Reconciliation 
 
All adverse events classified by investigators as serious are not only recorded on the CRF, but also 
directly communicated to the study sponsor. Such communication is done by the means of a 
separate form, where details of the event are described (67). Due to the inherent complexity of 
these events, the level of granularity of their reports and the regularity requirements for SAE 
reporting to the authorities, sponsor safety groups frequently use a specialized system for the 
processing and management of SAE data (49). 
 
However, since the CDMS is also a source of SAE data to be included in data analysis, reports and 
other documents supporting marketing authorization applications, it is paramount that SAE 
information matches in both databases. The process of comparing SAE information contained in 
the study database with SAE information in the sponsor’s safety database is called SAE 
reconciliation.  
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SAE reconciliation is performed to ensure consistency between the safety and the clinical study 
databases, not only in terms of the number of reported SAEs but also in terms of the content of 
predefined key data fields (68). When to reconcile is dependent on the study’s characteristics, 
namely frequency of data receipt, the scheduling of safety updates and the timing of interim and 
final reports (31). Study A, for which I had the opportunity to work in this task, is a long study so 
SAE reconciliation took place at regular points in time. The time intervals for SAE reconciliation 
are defined in advance, as well as a cut-off time, defined as the last point following study 
conclusion after which no new SAEs or updates will be added to the study database even if the 
safety database keeps on being updated (68). 
 
Ideally, SAE reconciliation should be done automatically by the two databases with the final result 
being a report indicating any existing discrepancies and their location on the database (69). 
However, this is rarely achievable because of the different ways the information is collected in the 
two systems. While a CDMS is comprised of highly structured forms with well-defined fields, 
safety systems impose less structure and information about each case is collected as a long, 
narrative text (49). These narratives are usually owned and managed by the sponsor. 
 
SAE reconciliation is thus carried out manually most of the times. The process can be initiated 
either by the CDM team or by the sponsor’s drug safety department. Whichever the case, the 
teams must exchange electronic or hard-copy listings generated from their respective databases 
(69). Reconciliation should only begin once all data to be reconciled have been entered and 
validated and the event has been coded (70). In the case of Study A, this was indeed a function of 
the study data manager and so a report with a copy of the SAE information was received and 
printed for comparison. 
 
As mentioned above, besides a comparison on the number of SAEs stored in both databases, a 
closer look is taken at each form to verify the consistency of key variables. For example (70): 
 Subject identification data 
 Description of event 
 Severity 
 Date of onset 
 Date event became serious 
 Outcome 
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 Action taken with study drug 
 Causality assessment 
 Date of resolution 
Possible issues include SAEs in the safety system that are not recorded in the CDMS or vice-versa 
(49). In terms of key field consistency, depending on what was agreed in advance, some items 
must be an exact match whereas others may be only similar but still acceptable (70). For 
instances, slightly different verbatim terms that do not affect medical coding are acceptable, as 
are recording of data in a different manner due to structural differences between databases. 
 
Where discrepancies are found, the study data manager issues a query to the study site for 
clarification. Fields which have been queried to the study site must be reviewed once again at a 
later time to check the resolution and decide: if the answer was not satisfactory and a re-query is 
needed; if the answer was satisfactory and demands an update of the clinical study database or of 
the safety database (68).  
 
3.2.4 Database Lock Activities 
 
In this section, I present and discuss the activities performed by the CDM team near the end of a 
clinical study, when study data is being finalized to be analyzed by the statistics team. Aspects 
concerning data storage and maintenance after the end of the study and the lock of the database 
are also presented. 
 
3.2.4.1 Final Database Quality Control 
 
As mentioned before, one of the priorities in clinical studies is to produce high-quality data that 
can be used to answer with accuracy and integrity the study’s research question. High-quality 
data is not, however, synonym to perfect data (13). The United States Institute of Medicine 
defines high quality data as “data strong enough to support conclusions and interpretations 
equivalent to those derived from error-free data” (71).  
 
So while high-quality data might admittedly not be free of errors, it possesses a level of quality 
that is considered acceptable for providing evidence of an investigational product’s safety and 
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efficacy. To ensure such a degree of quality, QC is applied to all stages of data handling during a 
clinical study. This is accomplished through a variety of procedures, including monitoring 
activities, double data entry (for paper-based studies), and manual and automatic edit checks, 
among others (56). 
 
As the study draws to a close, there is a particular focus on verifying and ensuring the quality of 
the database that is soon going to be handed over to a statistics group for analysis (49). It is a 
critical responsibility of the data manager to try to identify and understand the errors that were 
introduced in clinical study data at every step at which data was transcribed, transferred or 
otherwise manipulated. Errors that may have an impact on study results must be corrected and, 
when that is not possible, their impact on the validity of the study must be considered (31). 
 
As I learned from the final database QC activities I collaborated in, procedures to achieve this vary 
between paper-based and eDC-based studies. For Study R, a paper-based study, final database QC 
consisted of comparing the CRFs of a sample of study subjects with the data actually entered in 
the database for those subjects. For studies D and U, which were eDC-based studies, final 
database QC involved verifying if the DVP was implemented and worked as expected for a sample 
of study subjects, as well as performing a series of listing reviews on predefined datasets. 
 
As specified above, these procedures are typically not carried out for all study data, but for a 
statistically appropriate sample of such data instead. The revision of a statistically appropriate 
sample ensures that any findings are representative of the whole database and can be used to 
draw conclusions on the overall quality of study data (31).  
 
In order for the data manager to objectively conclude on the quality of the database, an error 
rate, defined as the number of errors found by the total number of data inspected, is calculated 
(13). If the error rate is deemed acceptable, the database is considered to be of acceptable quality 
for analysis and reporting. However, there are no regulatory dispositions or guidelines detailing 
what constitutes an acceptable data quality level, perhaps due to the diversity (and subsequent 
non-comparability) of QC methods used by different CDM teams. Choices of error rate vary and 
are usually not the same for critical and noncritical variables. Notorious error rates include 0.5% 
overall, 0% to 0.1% for critical variables and 0.2% to 1.0% for noncritical variables (13). At 
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Eurotrials, types of errors, formulas for error rate calculation and acceptable error rates are 
defined in a SOP. 
 
The procedure for the final database QC ends with the documentation of the sample size 
determination, errors found and actions taken to correct them, error rate calculations and overall 
conclusions on the acceptability of the study database in a Final Database QC Report. 
3.2.4.2 Database Lock 
 
Database lock is one of the final, and most critical, tasks of any CDM team responsible for a 
clinical study. Locking the database marks the end of the conduct of the study and the beginning 
of the final study data analysis and reporting (72). Locking a study database is crucial to avoid 
accidental or illegitimate changes to data once those activities have started. This is of particular 
relevance in randomized trials that had blinding procedures in place, and which have been broken 
for the purposes of the statistical analysis.  
 
Ideally, locking a database should mean that the database will not be re-opened in the future. 
This is not always the case, and clear change-control procedures for database unlock should exist 
for any clinical study. Nonetheless, best practice dictates that the CDM team follows a well-
defined and organized procedure to decrease the chances of unlocking a closed database. This 
procedure involves mostly confirming whether all data management steps and tasks have been 
completed.  
 
The following aspects are considered when assessing the adequacy of a database to lock (71)(70): 
 All study data have been received, accounted for and entered into the CDMS (applicable 
to paper-based studies). 
 All visits and assessments of all study subjects are completed or an acceptable 
justification exists for any missing data. 
 All data from various external sources have been successfully transferred into the 
database. 
 Data validation has been completed as per the DVP and all resulting queries have been 
resolved. 
 All required medical coding has been completed and reviewed for accuracy and 
consistency. 
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 SAE reconciliation has been completed and all discrepancies have been resolved 
(applicable where a separate safety database exists). 
 QC of the database has been completed and an acceptable error rate was achieved. 
 All documentation is updated and stored according to the SOPs in place. 
Additionally, the CDM team may participate (with members of the statistical, clinical and 
regulatory teams) in Data/Blind Review Meetings prior to database lock. These meetings are 
recommended by the ICH’s guideline on Statistical Principles for Clinical Trials (E9) as a way of 
checking and assessing study data to be used for the planned analysis (22). It encompasses the 
multidisciplinary appraisal of all tables, listings and summaries, the review of medical coding, the 
identification of all protocol deviations and the subsequent definition of populations for statistical 
analysis (73). 
 
Doing a statistical check for database acceptance, while very useful to ensure database quality 
and fitness for analysis, is rather uncommon (71). The fact is that statisticians look at the data 
slightly differently from data managers and they are capable of pinpointing issues that ultimately 
impact on primary endpoint or safety analysis. A joint review of data by the statistician and the 
data manager is thus an excellent method for preventing problems during data analysis (71).  
 
Once these tasks have all been considered completed by the CDM team, permission for locking is 
requested to the relevant stakeholders. In the case of a CDM team working in the context of a 
CRO, approval for database lock should be explicitly obtained from the client. As soon as the client 
gives the green light to the team, permissions to access and edit the data are removed, the 
database is locked and data is extracted for statistical analysis (65). The CDM team should release 
a signed certificate as a means to document the conclusion of the database lock procedures, 
specifying the point in time when edit access was removed (31, 49). 
In some cases, a technique known as soft database lock is employed. The term itself can refer to 
one of two things: to the temporary locking of the database done to enable an interim analysis 
(66); or to the process of incrementally locking the database to ensure a higher data quality and 
integrity. Soft database lock, as per the latter definition, is initiated slightly before the final (or 
hard) database lock. A soft-locked database does not allow record updates, but sites still can still 
respond to outstanding queries. This strategy is not routinely used, depending upon each client’s 
request. 
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After a database has been locked, no further changes to study data are permitted and, where 
blinding procedures exist, data unblinding is performed. This is accomplished by matching the 
codes in the randomization list to each patient unique ID and is an essential step before analysis 
can begin (66). 
 
Despite all the precautions taken, it is not impossible for errors to be found or for other critical 
issues to arise after the database has been locked. If such findings warrant that the database be 
unlocked to be corrected, the process for doing so should be carefully approved, controlled and 
documented (31). An audit trail has to be produced, accompanied by a proper justification for 
updating the previously locked database (65). In a CRO, database unlock should be required or 
approved by the client beforehand. Re-locking the database should follow essentially the same 
process as the initial lock, with appropriate quality control, review and approval (49).   
 
By contacting with the day-to-day reality of a CDM team, it becomes clear after a while that, on 
par with the initial study setup activities, database lock is one of the most significant milestones in 
the data management process and that time to study lock is one of the key data management 
metrics. Avoiding leaving things to be concluded near the end, optimizing performance and 
facilitating in-stream processing throughout the study phase are decisive to shorten the time to 
database lock and to do it with quality (54). 
 
3.2.4.3 Study Data Transfers 
 
Following database lock, it is the study data manager’s responsibility to release the study data to 
the statistician or to the sponsor. The format of the datasets should be predefined in advance. 
Generally they are exported from the clinical study database as SAS® files, since this is a validated 
application (49). 
 
When transferring clinical study data to the sponsor, the preferred method of transmission is 
through a secure File Transfer Protocol (FTP), a type of network protocol that allows for file 
transference between two remote systems over a secure connection (74). The underlying security 
of the FTP ensures compliance with regulatory guidelines concerning data confidentiality and 
authenticity protection (31). When the FTP system somehow fails to fulfill its purpose, two 
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possible alternatives for sending the database to the sponsor include regular e-mail and burning a 
CD-ROM which is afterwards sent via a courier. Similarly to other CDM procedures, transfers of 
data should be properly documented. 
3.2.4.4 Data Management Report 
 
The Data Management Report (DMR) is a report produced and released after database lock. The 
DMR is used to document deviations from the DMP (if any) that occurred during the course of the 
clinical study, to list all protocol deviations (as agreed with the sponsor), to provide conclusions 
and reflections on the status of the study data, to justify any missing data or queries that have not 
been solved, to provide information on adverse events recorded throughout the study and to 
document the procedures carried out to correct errors found after database lock (if any) (63). Its 
development is a responsibility of the study’s data manager. While it was not possible for me to 
prepare a complete DMR, I got familiar with the particulars of this task by observing and inquiring 
my colleagues whenever the opportunity presented itself. 
 
3.2.4.5 Data Archiving 
 
Like any other team involved in the conduct of a clinical study, the CDM team produces its fair 
share of documentation throughout a study. Documents are generated as evidence of when and 
how a given task was performed and by whom. Such documentation (including paper CRFs or 
electronic copies of final data extracted from the CDMS into SAS® datasets (31)) is filed in a hard 
copy and/or electronic filing system known as the Trial Master File (TMF). The TMF is intended to 
be a permanent, accurate record of how the various activities were carried out before, during and 
after the active phase of a clinical study. It should be a reflection of the professionalism and 
integrity of the CDM team and is used by the sponsor, regulatory bodies and internal audit teams 
to evaluate the conduct of the study and the quality of study data (66). 
 
As per ICH GCP requirements, data collected in a clinical trial and accompanying documentation 
are maintained for a minimum period of two years following the last regulatory submission 
involving the investigational product or the decision to discontinue its development (4). This 
period may be longer than two years, depending on each country’s national law. In Portugal, for 
example, data should be archived for at least five years after the conclusion of a clinical trial (75). 
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3.3 Summary of training experience 
Table 3 summarizes the clinical studies under the scope of which I developed the several CDM 
tasks. Depending on the opportunities that arose, as per the normal work dynamics of the SU, and 
on the complexity of the project, some activities were performed more often than others.  
 
Table 3 – Clinical studies under the scope of which I developed my internship activities. See Table 2 for a description of 
each study. 
 
As the table indicates, my training experience was a very complete one, whereupon I had the 
chance to work on every single CDM task at least once and under the scope of a multitude of 
clinical study designs and objectives, spanning a wide range of therapeutic areas.  
Tasks Study(ies) Identification. 
Data Management Plan D; I; N;  
Case Report Form design S; V;  
CRF Completion guidelines E;  
Database design A; B; I; L; N; Q 
Data Validation Plan  E;  
Database and Data Validation Plan validation C; E; H; P;  
Receipt and tracking of CRFs G; J; M; R; O; T 
Data entry G; M; O 
Data validation A; F; G; I; U 
Discrepancy management A; I 
Data standardization G; W 
Medical coding D; I; K; U;  
SAE reconciliation A 
Final database Quality Control D; R; U 
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4. Discussion 
My curricular internship at the Data Management SU of Eurotrials, Scientific Consultants, was 
focused on acquiring knowledge and experience on the projects and services falling under the 
scope of CDM. Over the course of 9-months, I got in touch with and participated in the activities 
typically developed by a data manager during clinical studies: preparing a  DMP, designing a CRF, 
designing a database and a DVP, validating a database and a DVP, entering data, validating data, 
coding data and more. 
 
While this is a very specific line of work, it provided me with a very interesting perspective on a 
clinical research project’s lifecycle. This perspective, unique on its own, was further enriched by 
the business reality I was working in – a CRO. 
  
Objectively, embarking on a curricular internship in CDM was the first great challenge of these 9 
months. It can be argued that, however comprehensive and diverse, neither the Bachelor’s 
degree in Biomedical Sciences nor the Master’s program in Pharmaceutical Medicine, provide 
foundations in CDM as solid as they do in other areas (e.g. Regulatory Affairs, Pharmacovigilance, 
etc.). I was admittedly intimidated by this lack of theoretical knowledge, and the widespread 
notion that CDM is a highly technical field that is difficult to understand. 
  
As expected, the first few weeks of this internship were very demanding. I was promptly included 
in the SU with the members of the CDM team. As I observed their work and listened to their 
explanations, I felt overwhelmed by the amount of new information, concepts and even technical 
jargon. Various CDMS were in use at the SU and each had its particularities. Some were not very 
user-friendly, especially for someone who does not have a background in Informatics. The tools 
provided by the Problem-Based Learning (PBL) methodology employed during my academic 
journey were key in overcoming these difficulties. 
  
PBL helped me develop a set of soft skills that proved of high value right at the beginning of my 
internship: proactivity, problem-solving skills, resourcefulness, critical thinking and autonomy. As 
soon as I identified the abovementioned difficulties, I decided to search for didactic materials on 
CDM and study them in parallel to my practical training. This was extremely useful to understand 
much of the theoretical ground that supports the practices of the CDM team. This, in turn, was 
crucial to make sense of the practical processes that I was increasingly involved in at the SU. 
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The same soft skills were also essential for me to grow as a professional in the company. I could 
easily adapt to and learn how to work in different tasks and respond to new challenges, and 
acquired a certain level of autonomy in a short amount of time. 
  
I was involved in projects dealing with both observational studies and clinical trials in various 
therapeutic areas employing paper-based CRFs and eDC. This allowed me to develop my CDM 
competences across a wide range of clinical research contexts, as well as to get to know the 
singularities of each type of data collection tool.  Overall, I believe I acquired a robust set of hard 
skills in the CDM domain that have prepared me to work professionally in this area. 
  
The success of my learning experience is also due to my colleagues’ constant availability to 
answer all of my questions. My doubts were never seen as inconvenient or absurd. Instead, I was 
encouraged to share them, especially whenever I was handed a new task. As my knowledge and 
experience progressed, I also felt my help, input and skills were valued by the team. This positive 
working environment definitely helped me overcome my initial feelings of insecurity and favored 
the accomplishment of the objectives of this internship. 
 
The simple fact of having transitioned very quickly from an academic environment to a 
professional environment was challenging to me. It took me some time to adjust to the whole 
work dynamic of a company, including having clearly defined working hours. However, with the 
support of all my colleagues, that period of adaptation went quite well. 
 
It is important to note that the multidisciplinary nature of my Bachelor’s degree and of the 
Master’s program proved to be of high value in the CDM setting, even if indirectly. The broad 
knowledge acquired in areas such as Anatomy, Physiology, Pharmacology and even Regulatory 
Affairs or Pharmacovigilance offered me many advantages. 
  
The CDM team is part of a larger team of specialists involved in a clinical trial, from CRAs to 
Statisticians. My previous knowledge enabled me to grasp the workflow, objectives, needs and 
expectations of these stakeholders. As I came to experience, this is crucial to facilitate 
communication and promote work efficiency. The knowledge I hold on Anatomy, Pathophysiology 
and Pharmacology proved to be an added-value skill in this setting. It offered me a privileged look 
into the data I was working with, allowing me to assess it critically. This was particularly helpful in 
62 
 
activities such as data validation and medical coding, as well as in understanding the scientific 
rationale behind the studies at hand. 
  
Unfortunately, clinical research professionals, unless they already have an extensive experience in 
working with CDM teams, seldom understand the requirements and the needs associated with 
the data manager’s deliverables. This is more impactful than I realized from the outset. 
Awareness should be raised among clinical research teams on the work of the clinical data 
manager, and for the importance of collaborating with them to ensure the generation of high-
quality clinical data. 
  
CDM is often regarded as an isolated field of work. While the data manager performs the core of 
his/her tasks alone, it is not possible to do them at all without interacting with the other study 
team members. For example, it is important to communicate with CRAs to understand what 
issues study sites are having with the CRFs, or with the Statistician to ensure that datasets were 
transferred seamlessly. In my SU, discussion between CDM colleagues on technical or practical 
aspects is frequent and a great way to learn more from each other’s experience. In some cases, 
these discussions led to the identification of needs that were met by developing new procedures 
or changing existing ones. This offered me an interesting, new perspective on what teamwork can 
be in the workplace and allowed me to develop my verbal and writing communication skills. 
  
The development of the curricular internship within a CRO allowed me to contact with a unique 
working environment. In this business model, the concerns inherent to carrying out a clinical 
research project (e.g. writing an adequate research protocol, getting a swift approval from Ethics 
Committees, recruiting the necessary number of patients, etc.) are magnified by the need to 
answer to the standards and requirements of an external client. Poor performances can have a 
significant impact on the company’s business. This helped develop a sense of responsibility that in 
every activity I participated in, notwithstanding the oversight by my SU colleagues. 
  
The fact that I had to deal with extensive files, containing great amounts of data, required me to 
be meticulous in my work. Furthermore, there are many standards that have to observed, 
including the company’s SOPs, to properly perform all activities. Accuracy and attention to detail 
minimize the risk of introducing errors that affect the validity of data and ultimately comprise the 
quality of a database. To that effect, being able to assess my work, the reasons behind any 
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mistakes and how to avoid them in the future was essential. Self-assessment was, thus, an ability I 
developed and came to see as a learning tool in itself. 
  
Deadlines for projects must be met consistently – this a requirement for any line of work, even 
more so in a CRO. Since I was often involved in several projects at the same time, it was essential 
that I established priorities and organized my day-to-day activities so as to conclude all tasks on 
time. This greatly improved my time management skills and, consequently, my productivity. 
  
Being involved in such projects as authoring an SOP or producing a template to be used by my 
colleagues was very stimulating. Despite never having been involved in projects of this nature, it 
was an excellent opportunity to discuss with my colleagues and it felt very satisfying to produce 
something of value for everyone. 
  
While I tried to make this a thorough and detailed account of the activities I developed during my 
curricular internship, it is impossible to translate into words neither the amount of effort I put into 
it nor the value and extent of the acquired knowledge. Moreover, there many details that I cannot 
share for confidentially reasons. Nevertheless, I wish to emphasize that these 9 months were 
filled with a number of excellent experiences and interactions that came together to make this 
one of the most deeply enriching enterprises of my academic journey. I will continue to grow 
professionally in the area of Clinical Data in the near future, with a willingness to keep on learning 
and taking on new challenges. 
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5. Conclusion 
Data that are generated by and/or collected in clinical studies of medicinal products are known as 
clinical data. These data are frequently the result of a major investment by biopharmaceutical or 
companies and are one of its most valuable assets - clinical data is paramount to prove the value 
of a product, eventually allowing it to be marketed. The management of clinical data has thus 
become a critical element in the development of medicinal products. The wide range of 
responsibilities, the variability in working tools and the interaction with multidisciplinary teams 
make CDM one of the most complex and diverse professions within clinical research. 
 
The curricular internship carried out at Eurotrials’ Data Management SU offered me an enriching 
and valuable insight into the practical work of the clinical data manager. This 9-month experience 
allowed me to understand the scope of activities and tasks of a CDM team during the course of a 
clinical study, including the difficulties that sometimes are faced and the satisfaction that comes 
from achieving the intended final result. I was allowed to participate in a multitude of projects 
within the Data Management SU. This resulted in a wide range of “hands-on” learning 
opportunities, complemented by a number of theoretical trainings. 
 
To work in CDM, as I came to learn, is not just about having strong technical skills. Contrary to 
what one might think from the outset, the CDM professional is in close contact with other clinical 
research professionals to carry out his or her tasks. Additionally, new challenges arise every day 
and issues emerge when one is least expecting them. This practical training was essential for me 
to work on the soft skills that are instrumental in this dynamic environment, including autonomy, 
proactivity, assertiveness and communication skills. 
 
The experience of working in a CRO was very challenging in itself. There are many principles and 
practices underlying this type of business that significantly shape the way by which its employees, 
including the CDM team, carry out their tasks. To be able to contact with this reality, so unfamiliar 
to me but of increasing importance in today’s clinical research environment, was very 
enlightening and instructive. 
 
The multidisciplinary knowledge acquired during the Bachelor’s degree in Biomedical Sciences 
and the Master’s program in Pharmaceutical Medicine proved to be a true asset on many levels. 
In its turn, undergoing this 9-month curricular internship provided me with the opportunity to 
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smoothly transition from the academic to the business world. Theoretical principles were seen 
put in practice and new concepts, ideas and realities were introduced. 
 
In conclusion, I believe that all objectives set forth for this curricular internship were effectively 
accomplished. This was a very successful, fulfilling experience that allowed me to grow 
academically, professionally and personally. 
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